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Chronic pulmonary diseases include a wide range of illnesses that differ in etiology, 
prevalence, symptomatology and available therapy. A common link among these illnesses 
is their impact on patients’ vital function of breathing, high symptom burden and 
significantly impaired quality of life. 
This dissertation research evaluates disease severity, symptom burden and health 
behaviors of patients with three different chronic pulmonary conditions. First, alpha-1 
antitrypsin deficiency (AATD) is an inherited condition that typically is associated with an 
increased risk of early onset pulmonary emphysema. This study examines differences in 
demographic, health, and behavioral characteristics and compares clinical outcomes and 
health related behaviors and attitudes between two severe genotypes of AATD - ZZ and 
SZ. The findings of the study suggest that patients with SZ genotype and less severe form 
of deficiency report higher number of exacerbations, comorbidities, as well as unhealthy 
behaviors such as lack of exercise and current smoking. In addition, individuals with the 
more severely deficient ZZ genotype are more adherent to disease management and 
prevention program recommendations and maintain a healthier lifestyle than individuals 
with SZ genotype.  
Second chronic lung disease examined in this research was chronic obstructive 
pulmonary disease (COPD), the fourth leading cause of death and second leading cause of 
disability in the United States. Prevalence and burden of cough and phlegm, two of the 
most common symptoms of the COPD, were assessed among participants of the COPD 
Foundation’s Patient-Powered Research Network (COPD PPRN). In addition, association 
between patient-reported levels of phlegm and cough, clinical outcomes and patients’ 
quality of life were evaluated. Participants’ quality of life was assessed using Patient 
Reported Outcome Measurement Information System instrument PROMIS-29. 
Association between changes in symptom severity over time and patient-reported quality 
of life were examined. Findings of this study indicated that severity of cough and phlegm 
were associated with higher number of exacerbations, greater dyspnea, and worsened 
     
 
patient-reported quality of life including physical and social functioning. Improvement in 
cough and phlegm severity over time was associated with better patient-reported quality of 
life. 
Third pulmonary illness described in this dissertation is non-cystic fibrosis 
bronchiectasis (NCFB), a rare and etiologically diverse condition characterized by dilated 
bronchi, poor mucus clearance and susceptibility to bacterial infection. Association 
between presence of Pseudomonas aeruginosa (PA), one of the most frequently isolated 
pathogens in patients with NCFFB, and disease severity was assessed utilizing enrollment 
data from the Bronchiectasis and NTM Research Registry (BRR). NCFB disease severity 
was evaluated using modified versions of validated in large international cohorts 
instruments, the Bronchiectasis Severity Index (BSI) and FACED. The findings of this 
study indicate that PA infection is common in NCFB patients, and presence of PA in 
patients’ sputum is associated with having moderate and high severity of bronchiectasis. 
In addition, the results of this study suggest that the two severity assessment instruments 
classify patients with NCFB differently which may be attributed to a greater number of 
severity markers utilized in the calculation of the BSI compared to FACED.  
In conclusion, the proposed dissertation aims to enhance understanding of 
differences in health outcomes between genotypes of AATD within AlphaNet registry, and 
to guide future health-promoting behaviors. It highlights the burden of common symptoms 
such as cough and phlegm in patients with COPD within COPD PPRN and their association 
with patients’ quality of life. In addition, it introduces modified indices of NCFB severity 
and emphasizes high burden of the disease in patients with presence of PA within US BRR. 
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CHAPTER 1.  INTRODUCTION 
Chronic pulmonary diseases, which include a wide range of illnesses of various 
lung structures, represent a growing public health problem and affect over a billion of 
people of all ages throughout the world.1,2 In the United States, chronic lower respiratory 
diseases are the fourth leading cause of death.3 Some of these illnesses are preventable 
and curable, while others still have no treatment available.4  
Despite the heterogeneity in their etiology, prevalence and presentation, all 
chronic pulmonary diseases affect individuals’ lungs and hence the vital act of breathing.4 
The burden of these conditions on people’s daily lives, as well as the economic burden to 
society in view of lost productivity, disability and healthcare costs is immense. 
Exacerbations, or acute flare-ups of symptoms, are common in people with chronic 
respiratory diseases, and associate with decreases in health-related quality of life 
(HRQOL) and increases in disease-associated mortality.5 
Many respiratory diseases, such as Chronic Obstructive Pulmonary Disease 
(COPD) remain highly prevalent in the United States (US) and worldwide. In 2015, over 
15 million adults in the US reported ever receiving a COPD diagnosis.6 In fact, the actual 
prevalence might be significantly higher considering that over 12 million adults may have 
undiagnosed COPD due to variations in diagnostic criteria.7,8 COPD is a  heterogeneous 
group of conditions that include chronic bronchitis, emphysema, and asthma 
components.9 It is characterized by symptoms related to airflow obstruction, such as 
chronic cough and production of sputum, dyspnea on exertion and wheezing.7 Presence 
of these symptoms along with the recurrent lower respiratory tract infections, history of 
risk factors such as smoking, environmental and genetic factors, and family history of 
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COPD, in an individual over age of 40 may indicate COPD and requires spirometry to 
establish a diagnosis.10  
 In COPD patients, burden of the disease is high. COPD patients suffer from 
chronic respiratory symptoms, fatigue, and often experience flare-ups of their symptoms 
that require physician or emergency room visits, change in therapy regimen, or even 
hospital admissions. Some of the main goals of COPD treatment are relief of symptoms 
and prevention of future excerbations.11 Previous research consistently found decreased 
HRQOL in patients with COPD, and its association with disease severity.11,12 Recent 
studies suggest symptom burden to be an appropriate marker for COPD disease 
severity.11 Thus, patient-perceived and reported symptom burden should be emphasized 
in COPD patient evaluation. HRQOL in patients with COPD is a composite measure that 
accounts for many psychological factors and other self-perceived patient experiences.13 
Patient-reported outcome measurement tools, such as Patient Reported Outcome 
Measurement Information System (PROMIS-29) have been validated and utilized to 
assess and incorporate COPD patients’ subjective experience in their disease severity 
assessment. 
Some illnesses under the umbrella of chronic pulmonary diseases are less 
common or even rare. In the US, a disease is considered rare if its prevalence does not 
exceed 200,000 individuals, or if it affects a greater number of people, but drug 
development and availability costs for the disease might not be potentially recovered 
from sales.14,15 Approximately 7,000 rare conditions affect estimated 30 million people in 
the US and lead to significant morbidity and mortality.16 Over 80% of rare diseases are 
genetically based and many are chronically debilitating.16 Alpha-1 antitrypsin deficiency 
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(AATD) is an autosomal codominant genetic condition that results in the production of 
defective Alpha-1 antitrypsin (AAT) protein.17 There are over 200 genetic variants of 
AAT. The two most frequent deficient alleles are PiZ and PiS.17 PiZZ genotype results in 
very low (below the protective threshold of 50 mg/dL) and PiSZ in below normal (less 
than 90 mg/dL) serum concentrations of AAT.18,19 Some researchers consider AATD not 
a rare but a rarely diagnosed illness.20 Lung disease in patients with AATD often presents 
with symptoms of COPD, and most commonly emphysema, and, thus is often 
misdiagnosed. AATD is considered one of the most common metabolic disorders among 
individuals of northern European descent.21 Low serum concentration of AAT and 
detection of genetic mutation assist in establishing the cause of patients’ COPD 
symptoms. AATD is estimated to affect one in 5,000-7,000 individuals in North America. 
Smoking, along with other environmental and occupational exposures, is one of the main 
factors influencing development of the lung disease regardless of genotype.21 Early 
diagnosis, healthy lifestyle, standard therapy for obstructive lung disease and, if 
indicated, periodic augmentation therapy to replace the deficient protein are the main 
disease management options in patients with AATD-related lung disease.21 
Another rarely diagnosed chronic pulmonary disease, non-cystic fibrosis 
bronchiectasis (NCFB), is inherently heterogeneous and is characterized by progressive 
and irreversible airway damage.22 Due to a complex pathophysiology involving infective, 
immune and inflammatory mechanisms, which chronically destruct bronchi in a so called 
“vicious cycle”, bronchiectasis patients require specific and long-term management.22,23 
Prevalence of NCFB continues to increase which may be explained by a greater 
awareness of the disease among clinicians and radiological advancements that aid in 
4 
 
accurate diagnosis.22 Some of the main presentations of bronchiectasis include chronic 
cough with sputum production, fatigue, hemoptysis, COPD symptoms in non-smokers, 
frequent respiratory infections and isolation of sputum pathogens such as Pseudomonas 
aeruginosa (PA) or Non-tuberculous mycobacterium (NTM).24 High resolution CT scan 
confirms the diagnosis of bronchiectasis.24  
Due to the complexity of various symptoms, recurrent exacerbations and 
hospitalizations, doctors’ visits, and frequent sputum microbiology and imaging testing, 
the burden of bronchiectasis on patients’ lives and healthcare systems is substantial.23,24 
Bronchiectasis severity is a multidimensional concept and use of multiple parameters is 
needed to capture the complexity of the disease burden and prognosis. The 
Bronchiectasis Severity Index (BSI) and the FACED have been developed and validated 
to improve the identification of high-risk NCFB patients and to guide therapy 
decisions.25,26 
The chapters that follow present studies that estimate disease severity, symptom 
burden and health-related behaviors in patients with the described above three chronic 
pulmonary conditions. In Chapter Two, “Comparing Patients with ZZ versus SZ Alpha-1 
Antitrypsin Deficiency within AlphaNet’s Disease Management Program”, demographic, 
clinical characteristics and health-related behaviors of patients with two most prevalent 
AATD genotypes, PiZZ and PiSZ, are evaluated. The major findings from this study 
identified that patients with ZZ and SZ genotypes in AlphaNet’s disease management 
program differ in health outcomes and health-related behaviors.27 Patients with SZ 
genotype had more comorbidities and were not as engaged in health-promoting behaviors 
compared to patients with ZZ genotype. ZZ patients were found to be more adherent to 
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the recommendations of the disease management program and maintained a healthier 
lifestyle than SZs. 
The study presented in Chapter Three, “The Burden of Cough and Phlegm in 
Chronic Obstructive Pulmonary Disease (COPD) Patients within the COPD Patient-
Powered Research Network (PPRN)” addresses the association between severity of 
cough and phlegm and quality of life in patients with self-reported physician-diagnosed 
COPD. The findings of this study identified that cough and phlegm severity levels were 
associated with higher number of exacerbations, greater dyspnea, and worsened patient-
reported quality of life including physical and social functioning and mood. The study 
results indicated that improvement in cough and phlegm severity over time were 
associated with better patient-reported quality of life. Exploration of new treatments 
aimed at improvement of cough and phlegm severity in this patient population were 
recommended. 
Findings presented in Chapter Four, “Pseudomonas aeruginosa Associated with 
Severity of Non-cystic Fibrosis Bronchiectasis Measured by the Modified Bronchiectasis 
Severity Score (BSI) and the FACED: the US Bronchiectasis and NTM Research 
Registry (BRR) Study”, supports previous research that PA infection is common in 
patients with NCFB. The study identified that the severity of bronchiectasis is 
significantly greater in patients with PA, which emphasizes the high burden of the 
disease. This chapter concludes that further collaborative work in this area are needed 
including exploration of new management options aimed at the improvement of patient 
outcomes and prognosis in PA infected NCFB patients. 
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Chapter Five of this dissertation provides summaries of major findings, discusses 




CHAPTER 2. COMPARING PATIENTS WITH ZZ VERSUS SZ ALPHA-1 
ANTITRYPSIN DEFICIENCY WITHIN ALPHANET’S DISEASE MANAGEMENT 
PROGRAM 
Abstract 
Background: The aim of this study was to examine differences in demographic, health, 
and behavioral characteristics in individuals with ZZ and SZ genotypes of alpha-1 
antitrypsin deficiency (AATD) within AlphaNet’s Disease Management and Prevention 
Program (ADMAPP). 
Methods: Self-reported data from 3,535 patients with AATD, including 3,031 (85.7%) 
patients with ZZ, ZNull, and NullNull genotypes (referred to here as ZZ), and 504 
(14.3%) with the SZ genotype were analyzed using t-tests, ANOVAs, and Chi-squared 
tests. 
Results: The average age of the cohort was 56.3±10.6 years. The majority of respondents 
were males (51.2%), Caucasians (98.2%), and married (65.2%). SZs reported having 
more frequent exacerbations (p<0.001) and hospitalizations (p=0.012) than ZZs. A higher 
proportion of SZs than ZZs had been diagnosed with high blood pressure, diabetes, 
congestive heart failure, and other comorbid conditions. SZs were more likely than ZZs 
to report “poor” health (p=0.005). Over a third (38.4%) of SZs do not exercise compared 
to 27.1% of ZZs (p<0.001). A greater proportion of SZs compared to ZZs view 
themselves as being overweight (p<0.001) or “out of shape” (p=0.001). A higher 




Conclusions: In patients with AATD and lung disease participating in a disease 
management program, a higher proportion of SZs than ZZs report exacerbations, 
comorbidities, and overall poor health, as well as unhealthy behaviors such as lack of 
exercise and current smoking. Future work should consider the extent to which genotype-
specific health promotion interventions would be useful. 
 
2.1 Introduction 
Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant disorder that 
results from mutations of the SERPINA1 gene and typically is associated with the 
elevated risk of early onset pulmonary emphysema28 in adults, liver disease in children 
and adults and, more rarely, necrotizing panniculitis.29 
SERPINA1 is considered a polymorphic gene.30 The PiM-allele represents the 
normal genotype.  The two most common mutations of the gene associated with AATD 
are the PiZ and PiS mutations, where Pi stands for “protease inhibitor”.31 Homozygous 
PiZZ is the most commonly identified severely deficient genotype while the PiS-allele 
leads to a milder plasma deficiency of AAT.30 Over 200 mutations of the gene have been 
discovered, with approximately one third of these mutations leading to clinically 
significant deficiency.31 Serum levels of AAT between 85 and 215 mg/dL are considered 
normal,32 although normal ranges vary by laboratory. Individuals with a ZZ genotype 
rarely have levels above 57 mg/dL, and levels below this value are presumed to provide 
inadequate lung protection.31  
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Both Z and S mutations are believed to have originated among populations of 
European (Caucasian) descent.33 The Z-gene is associated with the Scandinavian/Baltic 
region,34 and the S-gene is considered to derive from the Iberian peninsula.35 AATD can 
be found in all major racial subgroups in the world, although often at a very low 
frequency.36 
Previous studies that compared clinical features of SZ and ZZ patients have found 
significantly fewer respiratory symptoms, less severe airflow obstruction, and fewer 
radiographic lung abnormalities in SZ patients.37 Similarly, a study using the Spanish 
AATD registry (REDAAT) determined that ZZs have greater lung function impairment 
than SZs.35 The results of a large study in the UK demonstrated similar disease 
progression between SZs and ZZs although SZs had better baseline characteristics.38 
These findings were explained by the greater importance of AAT levels rather than 
genotype.38 Other studies have demonstrated a correlation of serum AAT levels with the 
severity of emphysema.39 Smoking is the major risk factor for development of lung 
disease in patients with AATD regardless of genotype.40,41 
It is important to know whether genotype is associated with health outcomes and 
health behaviors, in order to determine whether individuals with the SZ genotype have 
differing needs from ZZs with regard to health education and behavioral interventions 
such as smoking cessation. The primary aim of this study was to examine differences in 
demographic, health, and behavioral characteristics in individuals with ZZ and SZ 
genotypes among individuals who are participating in a disease management program 




The study population consisted of participants of AlphaNet, a not-for-profit health 
management organization that coordinates management and treatment of individuals with 
AATD and lung disease in the  US.42 Enrollment in ADMAPP is offered when an 
individual is prescribed plasma-derived, intravenous AAT for the treatment of lung 
disease due to AATD (augmentation therapy). Analyses were conducted on de-identified 
data collected by AlphaNet. The study was approved by the University of Kentucky 
Institutional Review Board (IRB).  
The inclusion criteria were that the participants were members of AlphaNet and 
had either a ZZ, ZNull, NullNull (analyzed in combination with ZZ) or SZ genotype of 
AATD. The final sample included 3,535 respondents (Figure 1). Of these, 3,031 (85.7%) 
were identified as ZZs. The ZZs can be broken down as follows: ZZ (n=2,979, 98.3%), 
ZNull (n=38, 1.2%), and NullNull (n=14, 0.5%). The present study analyses compared 
baseline characteristics of AATD patients with the ZZ genotype to those with the SZ 
genotype. All data were collected using questionnaires administered via a telephone 
interview. 
Statistical analyses 
Descriptive statistics were computed for baseline characteristics for the overall 
sample and stratified by genotype (ZZ vs. SZ). The results for continuous variables were 
reported as mean ( SD), and for categorical variables by frequencies and proportions. 
Values between the groups were compared using t-test/ANOVA, and Chi-squared test 
respectively. Post-hoc comparison of adjusted standardized residuals was used to 
determine the source of the statistically significant Chi-square for categorical variables. 
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Negative binomial (NB) regression models were fit for frequency of exacerbations and 
visits to a primary care physician in the past year adjusting for age, sex, smoking status 
and Charlson Comorbidity Index (CCI). A zero-inflated negative binomial (ZINB) model 
was fit for frequency of hospitalizations adjusting for the same covariates. The 
significance level for all analyses was set at 0.05. False discovery rate control was used to 
correct for multiple univariate testing.43 SAS 9.4 and SPSS version 22 were used to 
conduct analyses.  
2.3 Results 
Table 2.1 demonstrates the baseline demographic characteristics of the overall 
sample (n=3,535) and stratified by genotype: ZZ (n=3,031, 85.7%) and SZ (n=504, 
14.3%). Average age of the study population was 56.3±10.6 years. Patients with the ZZ 
genotype were slightly younger than SZs (55.9 years vs. 58.6 years, p<0.001), and a 
greater proportion of ZZs were Caucasians (98.4% vs. 96.8%, p=0.012), and reported 
being married (66.1% vs. 59.3%, p=0.004). The majority of respondents were male 
(51.2%) with no significant differences by genotype. Over ninety percent of all the 
respondents (92.7%) were on augmentation therapy with a greater proportion of ZZs than 
SZs (93.5% vs. 87.1%, p<0.001). The CCI score (which accounts for number and 
complexity of comorbidities) was significantly higher among SZs than ZZs (p<0.0001)44.  
A total of 3,274 (97.6%) patients reported ever having lung disease, with no 
significant difference between the genotypes. Emphysema/chronic bronchitis/COPD 




Among those who reported ever having lung disease, significant differences were 
found in exacerbation frequency between ZZ and SZ patients (p<0.001, Table 2.2). Based 
on post-hoc analysis using standardized residuals, a significantly greater proportion of 
SZs than ZZs reported having monthly (20.2% vs. 13.9%) and quarterly (21.3% vs. 
16.2%) exacerbations, while ZZs reported more semi-annual exacerbations (13.9% vs. 
9.6%). SZs did not differ from ZZs with regard to percent that used oxygen regularly, 
number of hours oxygen was used per day, or coughing up sputum regularly. 
The average number of visits to the primary care physician over the past year 
among all the respondents was 3.2±1.9, and to the lung specialist was 2.9±1.7. The mean 
number of hospitalizations was 0.7±1.3. SZs reported more primary physician visits 
(p<0.001), lung specialists visits (p<0.001) and hospitalizations (p=0.012) than ZZs. 
Table 2.3 presents the frequencies of the comorbidities within the overall study 
sample and stratified by genotype. The most frequent comorbidities were high blood 
pressure (40.3%), gastroesophageal reflux (34.8%), sinus disease (16.1%), heart rhythm 
problems (12.9%) and any tumor/cancer (11.9%). This study found that a statistically 
significantly greater proportion of SZs in the cohort were diagnosed with the six most 
prevalent comorbidities.  
Table 2.4 presents the results of self-reported health behaviors and fitness 
characteristics of ZZs and SZs. The majority of respondents reported having ever smoked 
(73.1%), and a significantly greater proportion of SZs than ZZs reported having ever 
smoked (p<0.001). In addition, SZs are more likely to continue to smoke (p<0.001), have 
been smoking longer (p<0.001), and report smoking more packs per day (p<0.001). 
Contrary to the findings for smoking, a higher proportion of ZZs report that they 
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consume alcohol (p=.009), and ZZs consume more drinks per week on average than SZs 
(p=.030). 
In view of self-perceived health and fitness, a significantly greater proportion of 
SZs than ZZs perceive themselves as being overweight (p<0.001), out of shape (p=0.001) 
and in “poor health” (p=0.005). More ZZs report that they exercise regularly compared to 
SZs, and 38.4% of SZs do not exercise at all compared to 27.1% ZZs (p<0.001).  
The majority of patients reported that they follow the guidelines of ADMAPP 
(53.5%), and a significantly greater proportion of ZZs report following the program 
compared to SZs (p=0.026). Almost a half of the participants (49.2%) reported ever 
reading the BFRG with no difference by genotype.  
Most patients reported being very comfortable with their knowledge about AATD 
(51.1%). However, significant differences were found between the genotypes (p<0.001). 
Specifically, a greater proportion of SZs, when compared to ZZs, reported being either 
“not comfortable” (9.8% vs. 4.0%) or “somewhat comfortable” (55.0% vs. 42.2%) with 
knowledge about their condition.  
Table 2.5 presents results of the adjusted NB and ZINB models. The criteria for 
assessing goodness of fit of each of the regression models showed adequate fit: deviance 
(scaled deviance) value/DF and Pearson Chi-Square (Scaled Pearson) value/DF were 
reasonably close to 1 (between 0.95 and 1.18) which indicates adequate fit of the models 
to the data. The selected regression models showed superior fit using Vuong test and 
AIC, AICC, and BIC criteria, when compared to other types of count models.  
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As demonstrated in Table 2.5, genotype was associated with the number of 
exacerbations and visits to a primary care physician after adjusting for age, gender, 
current smoking status, and CCI score. SZs had 1.21 times the rate of pulmonary 
exacerbations (IRR=1.21, 95% CI: 1.05-1.40) and visits to a primary care physician 
(IRR=1.21, 95%CI: 1.12-1.30) in the past year compared to ZZs.  
2.4 Discussion 
Earlier work by Turino et al.37 described clinical features of a relatively small 
number of patients with the SZ genotype of AATD and AAT concentrations above or 
below 11 µM (~57 mg/dL), including the effects of smoking on development of lung 
disease in SZs. More recent studies comparing characteristics of individuals with the ZZ 
and SZ genotypes were mainly carried out in Europe35,38,45 as the prevalence of S-allele is 
the highest in the general population of Spain and Portugal (17.3 and 13.8 per 1,000, 
respectively).46  
Although any individual with AATD can enroll in AlphaNet’s disease 
management program, the vast majority of individuals entered because of a prescription 
for augmentation therapy for lung disease due to AATD. Individuals not receiving 
augmentation therapy are moved to a different program within AlphaNet that focuses on 
risk reduction: Risk Evaluation to Ensure Continued Health (REACH). Thus, the 
population described here is greatly enriched for individuals with lung disease due to 
AATD. Since individuals with the SZ genotype are considerably less likely to develop 
lung disease than ZZs,37 many of the differences reported in this study may be reflective 
of the subpopulation of SZs with risk factor exposure sufficient to have led to clinically 
significant lung disease. Risk for development of lung disease is associated with the 
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interaction between genetic factors and various environmental exposures such as 
smoking.40  
Prior studies have noted higher mean smoking consumption of SZs compared to 
ZZs.47 This study findings complement these observations by showing that when 
compared to ZZs, SZs had a significantly longer smoking history with greater number of 
packs smoked per day. Further, the SZs in our sample were more likely to continue 
smoking after being diagnosed with lung disease. These results reflect the importance of 
emphasizing behavioral interventions and health education including smoking cessation, 
especially among SZs, as well as early diagnosis of AATD prior to the development of 
heavy smoking habits.47  
Exacerbations commonly occur among patients with AATD-related lung disease48 
and, in previous research, were demonstrated to be associated with a decline in lung 
function.48 In our sample, SZs reported more frequent exacerbations than ZZs, even after 
adjusting for age, sex, current smoking status and CCI score. Possible explanations 
include greater prior exposure to smoking, and lower adherence to healthy lifestyle 
recommendations, including adherence to AlphaNet’s disease management program. 
However, lack of pulmonary function data limited our ability to compare lung disease 
severity between genotypes.  
Previous research has demonstrated an association between AATD and certain 
comorbidities, such as ulcerative colitis and hypothyroidism49 among ZZs. Other studies 
demonstrated associations between ZZ and MZ genotypes of AATD and reduced blood 
pressure, as well as MZ and reduced risk of ischemic cerebrovascular and ischemic heart 
disease.50,51 This study results show a significantly higher prevalence of cardiovascular 
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comorbidities, including hypertension, cerebrovascular disease, congestive heart failure, 
and arrhythmia among SZs compared with ZZs. The reasons for this association with SZ 
genotype are not well understood, nor sufficiently investigated previously. It should be 
noted that SZs in our cohort are slightly older than ZZs; also, the diagnosis of AATD 
may prompt a more thorough assessment for other health problems among SZs. 
Additionally, our findings of unhealthy lifestyle of the majority of SZs in this study 
population, may have contributed to the greater prevalence of cardiovascular 
comorbidities among patients with this genotype. 
Previous research has explored the effects of genetic information on health 
behaviors of patients and their families.52-56 These studies have found inconsistent results 
with regard to the effect of genetic information on smoking cessation and motivation to 
improve diet and physical activity. The present study demonstrated that ZZs and SZs 
significantly differ in their perception of health and fitness as well as their health 
behaviors. A greater proportion of SZs viewed themselves as overweight, out of shape 
and in poor health, and they also exercise less and report heavier and longer history of 
smoking compared with ZZs in our study. These findings may be explained by the 
perception that the SZ genotype presents a lower risk of the disease in view of the higher 
AAT levels in plasma. Our findings with regard to alcohol consumption suggest that, 
regardless of genotype, additional education about moderation of alcohol consumption 
should be considered due to the increased risk of liver disease among individuals with 
AATD. 
ADMAPP is a vital part of AlphaNet’s commitment to improve patients’ health 
outcomes.42,57 The present study shows that a significantly lower proportion of SZs report 
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following the guidelines of ADMAPP compared to ZZs. This lower adherence to the 
program may be due to the earlier mentioned concept of the low self-perceived 
seriousness of their condition. It should also be noted that SZs are less comfortable with 
the level of their knowledge about AATD compared to ZZs.   
Our results suggest that, among individuals with AATD who have developed lung 
disease, people with a less severe genotype who develop lung disease have worse health 
outcomes and health behaviors. Thus, the people who are less at risk (from a genetic 
standpoint) to develop lung disease may actually do worse once they have developed 
lung disease. While prevention efforts may need to be targeted to ZZs (since they are 
most at risk to develop disease) it is possible that disease management may be even more 
vital to SZs. 
Understanding differences and similarities between various genotypes of AATD 
is of great importance from the public health perspective. Early knowledge and 
awareness of AATD allows for timely testing, smoking prevention and cessation, and 
initiation of augmentation therapy when indicated.58  
Strengths and limitations 
The main strengths of the present study include a large number of patients with 
AATD-related lung diseases enrolled in the disease management program, as well as 
unique data on multiple health-related behaviors collected by AlphaNet. 
Several limitations must be acknowledged. First, a considerably larger fraction of 
ZZs develop lung disease compared with SZs. Since only patients with lung disease were 
invited to participate in ADMAPP, this may have introduced ascertainment bias into the 
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study. Although, both SZs and ZZs were enrolled based on the presence of lung disease. 
This study provides no information about the comparative characteristics of SZs and ZZs 
without lung disease. Second, causality cannot be inferred due to the cross-sectional 
design of this study. Third, objective data were not available to provide more specifics on 
clinical phenotyping of lung disease, including CT findings and lung function 
measurements. Another limitation of this study is unavailability of the actual date of 
AATD diagnosis in most patients, which limits our ability to account for the length of 
time since diagnosis. The benefits of earlier age at diagnosis might be reflected in 
behavior modifications such as smoking cessation or improved exercise habits, which 
might contribute to better outcomes.  
2.5 Conclusion 
In summary, the results of this study document that ZZ and SZ patients in 
AlphaNet’s disease management program differ with regard to health outcomes and 
health behaviors. Individuals with the SZ genotype report more comorbidities and are 
less likely to engage in health-promoting behaviors such as exercise and smoking 
cessation. It appears that individuals with the more severely deficient ZZ genotype are 
more adherent to ADMAPP recommendations and maintain a healthier lifestyle than 
individuals with the less severely deficient SZ genotype. As such, improvements in 
education efforts may be especially beneficial for individuals with the SZ genotype who 
have lung disease, even though their underlying AATD is considered to be less severe.  





Table 2.1  Select demographic and clinical characteristics of the overall sample and 











Age, mean (SD) 3,535 56.3 (10.6) 55.9 (10.5) 58.6 (11.2) <.001 
Male 3,535 1,808 (51.2) 1,535 (50.6) 273 (54.2) .143 
Race/ Ethnicity 3,475    .012 
Non-Hispanic 
Whitea 
 3,412 (98.2) 2,935 (98.4) 477 (96.8)  
African-
American 
 14 (0.4) 13 (0.4) 1 (0.2)  
Hispanica  29 (0.8) 20 (0.7) 9 (1.8)  
Othera  20 (0.6) 14 (0.5) 6 (1.2)  
Married 3,417 2,227 (65.2) 1,938 (66.1) 289 (59.3) .004 
Employed  3,135 1,118 (35.7) 997 (36.8) 121 (28.5) .002 
Augmentation use 2,842 2,634 (92.7) 2,330 (93.5) 304 (87.1) <.001 
History of any 
lung disease 




3,204 3,100 (96.8) 2,681 (96.9) 419 (95.7) .165 
Asthma 3,031 1,144 (37.7) 993 (37.8) 151 (37.2) .806 
Pneumonia 2,995  520 (17.4) 453 (17.4) 670(17.0) .822 
Bronchiectasis 2,999 292 (9.7) 263 (10.1) 29 (7.29) .077 
Charlson 
Comorbidity 











Note: All statistics are reported as frequency (percentage) unless otherwise indicated. 




Table 2.2  Exacerbations, hospitalizations, oxygen use and physician visits in the overall 











Exacerbation frequency of 
lung problems over the 
past yeara 
Every Month c 
Every 3 Months c 
Every 4 Months 




































Number of exacerbations 
of lung problems over the 
















Regular oxygen usea 2,943 1,515 (51.5) 1,333 (52.2) 182 (46.9) .053 
Regular Oxygen usea, 












Regularb coughing up 
sputum from lungs over the 











Primary physician visits 












Lung specialist visits over 











Hospitalizations over the 











Note: All statistics are reported as frequency (percentage) unless otherwise indicated. 
a denotes frequency among patients with any type of lung disease, b denotes frequency of 
at least three months per year over the past two years, c denotes statistically significant 




Table 2.3  Frequencies of the comorbidities reported by the respondents in the overall 
sample and stratified by genotype 




























1,077 (34.8) 903 (33.9) 174 (40.4) .008 a 
Sinus disease 499 (16.1) 
 
411 (15.4) 88 (20.4) .009 a 
Heart rhythm problem 
 
399 (12.9) 319 (12.0) 80 (18.6) .001 a 
Any tumor or cancer 
 










Skin problems (such as 
panniculitis) 
 
258 (8.3) 228 (8.6) 30 (7.0) .269 
Pulmonary hypertension 
 
204 (6.6) 169 (6.3) 35 (8.1) .165 
Peripheral vascular disease 
 
199 (6.4) 169 (6.3) 30 (7.0) .623 
Connective tissue disease 
 
192 (6.2) 160 (6.0) 32 (7.4) .254 
Mild liver disease 
 
183 (5.9) 155 (5.8) 28 (6.5) .580 
Ulcer Disease  
 
172 (5.6) 137 (5.1) 35 (8.1) .012 a 
Inflammatory bowel disease 
 
169 (5.5) 138 (5.2) 31 (7.2) .087 
Severe eye problems 
 
136 (4.4) 111 (4.2) 25 (5.8) .123 
Congestive heart failure 
 
119 (3.8) 89 (3.3) 30 (7.0) <.001 a 
Myocardial infarction 
  
108 (3.5) 80 (3.0) 28 (6.5) <.001 a 
Hepatitis 
 
103 (3.3) 83 (3.1) 20 (4.6) .100 
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Table 2.3 Continued     







Moderate or severe liver disease 
 
95 (3.1) 80 (3.0) 15 (3.5) .590 
Cerebrovascular disease 
 
91 (2.9) 66 (2.5) 25 (5.8) <.001 a 
Mild kidney disease 
 
72 (2.3) 63 (2.4) 9 (2.1) .864 
Moderate or severe kidney 
disease 
 




38 (1.2) 34 (1.3) 4 (0.9) .812 
Paralysis of arms and/or legs 
 
24 (0.8) 16 (0.6) 8 (1.9) .012 a 
Dementia or Alzheimer’s 
 
16 (0.5) 14 (0.5) 2 (0.5) .999 
Metastatic cancer 
 
13 (0.4) 12 (0.5) 1 (0.2) .999 
Lymphoma 
 
11 (0.4) 11 (0.4) -- -- 
Leukemia 
 
7 (0.2) 4 (0.2) 3 (0.7) .061 
AIDS 
 
2 (0.1) 1 (0.1) 1 (0.2) .259 
Note: All statistics are reported as frequency (percentage) unless otherwise indicated. a -





Table 2.4  Self-reported health behaviors and fitness characteristics in the overall sample 











Ever smoking history 3,105 2,270 (73.1) 1,937 (72.0) 333 (80.6) <.001 
Still smoking 2,257 106 (4.7) 68 (3.5) 38 (11.5) <.001 














































Do you exercise 3,103    <.001 
No a  888 (28.6) 729 (27.1) 159 (38.4)  
Irregularly  1,071 (34.5) 945 (35.1) 126 (30.4)  
Regularly a  1,144 (36.9) 1,015 (37.8) 129 (31.2)  
Perception of weight 3,077    <.001 
Underweight  349 (11.3) 299 (11.2) 50 (12.2)  
About Right a  1,249 (40.6) 1,123 (42.1) 126 (30.7)  
Overweight a  1,479 (48.1) 1,244 (46.7) 235 (57.2)  
Perception of fitness 3,054    .001 
Out of Shape a  1,396 (45.7) 1,179 (44.5) 217 (53.7)  
Getting Fit  606 (19.8) 525 (19.8) 81 (20.1)  
Pretty Fit a  957 (31.3) 860 (32.5) 97 (24.0)  
Very Fit  95 (3.1) 86 (3.3) 9 (2.2)  
Perception of health 3,069    .005 
Poor a  529 (17.2) 436 (16.4) 93 (22.6)  
Fair  1,272 (41.5) 1,112 (41.8) 160 (38.9)  
Good  1,136 (37.0) 988 (37.2) 148 (36.0)  
Excellent a  132 (4.3) 122 (4.6) 10 (2.4)  
Follow ADMAPP 2,412 1,291 (53.5) 1,154 (54.4) 137 (47.4) .026 
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Ever read BFRG 
 











    
<.001 
No a  167 (4.9) 119 (4.0) 48 (9.8)  
Somewhat a  1,513 (44.0) 1,244 (42.2) 269 (55.0)  
Very a  1,758 (51.1) 1,586 (53.8) 172 (35.2)  
Note: All statistics are reported as frequency (percentage) unless otherwise indicated. 
a denotes statistically significant difference based on post hoc analysis using standardized 
residuals, BFRG- Big Fat Reference Guide, ADMAPP- Alphanet’s Disease Management 
and Prevention Program 
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Table 2.5  Results of adjusteda analyses comparing patients with SZ versus ZZ genotype 
Outcome  Parameter 
Estimateb (SE) 
P-value Rate Ratio 95% CI
Frequency of pulmonary 
exacerbations in the past 
yearc 
0.20 (0.07) 0.0074 1.21 (1.05-1.40) 
Frequency of 
hospitalizations in the past 
yeard 
0.21 (0.11) 0.0564 1.23 (0.99-1.52) 
Frequency of visits to a 
primary care physician in 
the past yearc 
0.19 (0.04) <.0001 1.21 (1.12-1.30) 
a adjusted for age, gender, current smoking status, and CCI score, bParameter Estimate 
(SE) for SZ genotype, cresults of negative binomial regression, dresults of zero-inflated 













CHAPTER 3. THE BURDEN OF COUGH AND PHLEGM IN CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS WITHIN THE 
COPD PATIENT-POWERED RESEARCH NETWORK (PPRN) 
Abstract 
Rationale: Cough and phlegm are common in patients with COPD and significantly 
affect the quality of their day-to-day lives. The main objectives of this study were to 
estimate the prevalence and assess the burden of cough and phlegm among patients with 
a self-reported physician-diagnosed COPD, and to determine if an association is present 
among reported levels of phlegm and cough, clinical outcomes and patients’ quality of 
life. 
Methods: Patient-reported data from the COPD Foundation’s Patient-Powered Research 
Network (COPD PPRN) were used for this study. Severity of cough and phlegm were 
assessed according to patients’ responses on COPD Assessment Test. Burden of cough 
and phlegm on patients’ quality of life was evaluated using the Patient-Reported 
Outcome Measurement Information System (PROMIS-29) instrument. Associations 
between the seven domains of PROMIS-29 and the severity of cough and phlegm were 
examined using MANOVAs. PROMIS-29 domain scores at follow-up were evaluated 
stratified by changes in self-reported cough and phlegm severity levels between baseline 
and follow-up. 
Results: The average age of the study participants (n=5,286) was 64.4 years (SD=11.5), 
95.3% white, 60.4% female, 51.2% married, and 42.2% had caregivers. Patients with 
moderate/high cough (73.1%) or phlegm (67.9%) had significantly worse dyspnea 
(p<.0001), greater number of exacerbations in the past 1 year (p<.0001), and worse 
quality of life compared to those with no/low cough and phlegm. PROMIS-29 scores at 
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follow-up were significantly associated with changes in cough and phlegm severity over 
time. 
Conclusions: In patients with COPD, severity of cough and phlegm were associated with 
greater number of exacerbations, greater dyspnea, and worsened patient-reported quality 
of life including physical and social functioning. Improvement in cough and phlegm 
severity over time was associated with improvement of patient-reported quality of life. 
 
3.1 Introduction 
Chronic obstructive pulmonary disease (COPD) affects between 15 and 25 
million adults in the United States (US), and is the fourth leading cause of death and the 
second leading cause of disability.8,59,60 In the US, COPD is estimated to be responsible 
for over 10 million physician office visits, 1.5 million emergency room department visits, 
and approximately 700,000 hospitalizations annually.8,61 The direct and indirect cost 
burden of COPD in the US are estimated at over $50 billion.8,62 Actual burden of COPD 
is significantly higher considering that patients with COPD often have multiple comorbid 
conditions.7 
COPD assessment includes several criteria such as symptom burden, exacerbation 
history, and airflow obstruction.8,63 The most recent Global initiative for chronic 
Obstructive Lung Disease (GOLD) guidelines emphasizes focus on patients’ symptoms 
in evaluating disease severity.63 Some of the most commonly reported symptoms of 
COPD are cough, dyspnea, sputum production, and wheezing, which largely depend on 
the stage of the disease. Cough, along with mucus production, is frequently among the 
first reasons for seeking help from medical professionals among patients with COPD.64  
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The association between COPD symptom severity and health-related quality of 
life (HRQOL), including its physical, social function and psychological aspects, was 
highlighted in published literature and attributed to the “humanistic” burden of the 
disease.65 Additionally, the burden of nighttime COPD symptoms, especially cough and 
production of mucus, on patients’ quality of life and sleep further contributes to increased 
mortality and morbidity in this patient population.66 COPD symptom experience was 
identified as closely related to patient health outcomes.67,68    
However, little research has been conducted to specifically address patient-
reported burden of cough and phlegm on functional status, role fulfillment abilities and 
impact on mood and sleep. Symptom severity perception as a subjective patient 
experience is best evaluated using patient-reported data and patient-reported outcome 
instruments.69  
The main objectives of this study were to estimate the prevalence and assess the 
burden of cough and phlegm among patients with a diagnosis of COPD within COPD 
Foundation’s Patient-Powered Research Network (COPD PPRN) community, and to 
determine if an association is present between reported levels of phlegm and cough, 
clinical outcomes and patients’ quality of life. Secondary objectives of the study were to 
evaluate associations between changes in cough and phlegm severity levels over time and 
patients’ self-reported quality of life. 
3.2 Methods 
Our study used data from the patient-reported information collected by the COPD 
PPRN. This secure online interactive patient registry maintained by the COPD 
Foundation (COPDF) and funded by Patient-Centered Outcomes Research Institute 
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(PCORI) and the COPDF, enrolls patients with self-reported physician diagnosed COPD 
or risk factors for COPD. The COPD PPRN data used for the present study included only 
individuals with a self-reported physician-diagnosed COPD, and excluded patients with 
risk factors for but no diagnosis of COPD. Demographic information such as age, gender, 
race, and ethnicity, COPD-related clinical information including COPD Assessment Test 
(CAT) scores, frequency of exacerbations, dyspnea severity, as well as presence of 
various comorbid conditions, smoking status, and other patient characteristics were 
collected at the time of enrollment and completion of eConsent.   Severity of symptoms, 
burden of the disease and comorbidities as well as patient-reported outcomes are reported 
for all patients at time of enrollment, and for a smaller subset of enrollees who have 
completed baseline and follow-up surveys.    
CAT was used to assess the frequency and severity of patients’ cough and 
phlegm.70 CAT is a well-validated patient-completed questionnaire that measures eight 
various symptoms of COPD (cough, phlegm, chest tightness, breathlessness going up 
hills and stairs, activity limitation at home, confidence leaving home, sleep, and energy) 
on a 0 - 5 point Likert-type scale.70 CAT was designed to assist health professionals in 
quantifying burden of COPD symptoms on patients’ health status.71 Question 1 assesses 
frequency of cough and is anchored by “I never cough” and “I cough all the time” 
questions. Question 2 assesses severity of phlegm and is anchored by questions “I have 
no phlegm (mucus) in my chest at all” and “My chest is completely full of phlegm 
(mucus)” (Figure 3.1). Scoring range of CAT inclusive of all eight questions is 0-40 with 
higher scores reflecting more severe burden of COPD symptoms. Suggested scoring 
interpretation is low impact <10, moderate impact 10-20, high impact 21-30, and very 
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high impact >30. Considering that our study is assessing the burden of only two COPD 
symptoms, for the purposes of the present analyses, frequency and severity of cough and 
phlegm levels were stratified into three categories according to the responses on 
questions 1 and 2 of CAT: 1) 0-1 no/low, 2) 2-3 moderate and 3) 4-5 high. Additionally, 
for some of the descriptive analyses, cough and phlegm severity levels were 
dichotomized according to CAT scores of the respective components: 1) 0-1 no/low, and 
b) 2-5 moderate/high. The joint effect across severity levels of cough and phlegm was 
calculated and classified into four categories: 1) no or low cough/no or low phlegm, 2) no 
or low cough/moderate or high phlegm, 3) moderate or high cough/no or low phlegm and 
4) moderate or high cough/ moderate or high phlegm. 
Modified Medical Research Council (mMRC) Dyspnea Scale items were 
collected and used to measure functional impairment due to shortness of breath in 
patients with COPD. mMRC rates patient-reported perception of dyspnea severity on a 0-
4 Likert-type scale.72,73 
Patient Reported Outcome Measurement Information System (PROMIS-29) 
instrument was used to evaluate burden of cough and phlegm on patients’ quality of life 
and specific functional abilities such as social and physical role functioning.74,75 
Specifically, the PROMIS-29 profile instrument was designed to be used in people with 
chronic conditions and encompasses 7 domains (Depression, Anxiety, Physical Function, 
Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles 
and Activities), with 4 questions for each domain.76,77 Data were collected at enrollment 
and 12 months later at follow-up. Each of the questions had five response options scored 
1-5. The total raw score of each domain ranged between 4 and 20 and was calculated as a 
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sum of score values for each question. Scoring of the PROMIS-29 domains requires all 
questions within a specific domain to be answered. Raw scores for each domain were 
then converted to standardized T-scores with a mean of 50 (SD=10) using scoring tables 
specific to each of the domains. Per PROMIS-29 scoring guidelines, for 5 out of 7 
domains, a score of 50 represented the average for the general US population, and for 
Ability to Participate in Social Roles and Activities, and Sleep Disturbance, a score of 50 
represented the average of a calibration sample enriched for chronic morbidities.76 For 
negatively worded concepts, such as Depression or Fatigue, higher PROMIS-29 T-score 
(above 50) was worse as it represented more of the negative concept being measured. 
Whereas, for positively worded concepts such as Ability to Participate in Social Roles 
and Activities, higher PROMIS-29 T-score (above 50) was better.   
Charlson Age-Comorbidity Index (CACI) was calculated using information on 
self-reported illnesses to measure the burden of comorbidities. CACI is a validated tool 
designed to predict patient outcomes according to age and comorbid conditions.78 It 
incorporates 19 medical conditions weighted 1-6 points, and scores also receive an 
additional point for every decade increase above the age of 50 years.  
One year after completion of the baseline survey, patients were eligible to 
participate in the follow-up survey. Among various follow-up characteristics of the 
patients, data on CAT and PROMIS-29 scores were collected. PROMIS-29 follow-up 
scores were computed and standardized according to the same scoring guidelines as 
baseline scores. According to the changes in severity levels of cough and phlegm 
between baseline and follow-up patients were stratified into four categories: 1) improved 
- patients with moderate/high severity levels at baseline and no/low severity at follow-up; 
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2) worsened - patients with no/low severity levels at baseline and moderate/high severity 
at follow-up; 3) patients who maintained no/low severity at baseline and follow-up, 4) 
patients who maintained moderate/high severity at baseline and follow-up.  
Statistical Analyses 
Descriptive statistics were computed and reported as mean (SD) for continuous 
variables, and frequencies and proportions for categorical variables. Stratified analyses of 
main demographic (age, gender, race/ethnicity, smoking status) and clinical 
characteristics (CAT, mMRC, CACI, exacerbation frequency, 7 domains of PROMIS-29) 
were performed by severity levels of cough and phlegm. Values between the strata were 
compared using Chi-square tests for categorical variables and t-tests for continuous 
variables. Correlations between cough and phlegm severity levels, and the correlation 
between current cough and phlegm severity levels and presence or absence of cough or 
phlegm for at least three months per year in the past two years were evaluated using 
Kendall's tau-b. Standardized scores of PROMIS-29 domains were calculated and 
reported as mean (SD) in the overall sample and stratified by cough and phlegm severity 
levels.  
Correlations between seven domains of PROMIS-29 were assessed using Pearson 
correlation coefficients. Joint effect of severity of both symptoms was calculated across 
cough and phlegm severity levels. One-way multivariate analysis of variance 
(MANOVA)79 was conducted to identify mean differences between joint severity levels 
of cough and phlegm and standardized scores of seven PROMIS-29 domains. Follow-up 
ANOVAs and a series of post-hoc Fisher’s LSD tests were performed to examine 
individual mean difference comparisons across all levels of the combined symptoms 
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severity and all seven PROMIS-29 domains’ scores. Adjusted associations between 
PROMIS-29 domains and severity levels of both cough and phlegm were evaluated 
controlling for age, gender, and smoking history.  
Associations between seven PROMIS-29 domain scores at follow-up and the four 
categories of changes in cough and phlegm severity levels between baseline and follow-
up were examined using MANOVA. Missing data analyses were performed to compare 
select baseline characteristics of the patients included in the follow-up data analyses 
versus those with missing follow-up data. The significance level was set at 0.05. All 
statistical analyses were performed using SAS 9.4. 
3.3 Results 
Of the 5,314 respondents with self-reported physician-diagnosed COPD who 
participated in the survey, 5,286 respondents had data to assess the severity of cough and 
phlegm and were included in the baseline analyses (Figure 3.2). The majority of the 
patients were women (60.4%) with a mean age of 64.4 years (SD=11.5), predominantly 
white (87.9%), approximately half of them were married (51.2%), and 42.2% had 
caregivers. Most of the respondents (88.2%) reported a history of ever smoking with an 
average of 45.5 packs/year, and 17.8% of them were current smokers.  
Moderate/high levels of cough were reported by 73.1% of the patients and 
moderate/high levels of phlegm by 67.9% of the patients. Respondents with 
moderate/high cough and phlegm severity were younger compared to those with no/low 
levels of these symptoms (p<.0001). No statistically significant differences were found in 
other demographic characteristics between the strata by cough or phlegm severity (Table 
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3.1). A significantly greater proportion of patients with moderate/high levels of cough 
(19.0%) and phlegm (19.8%) reported being current smokers compared to those with 
no/low cough and phlegm (5.7% and 6.5%, respectively, p<.0001). Those with 
moderate/high cough and phlegm had significantly worse self-reported dyspnea as 
measured by mMRC (p<.0001), and greater number of exacerbations in the past 1 year 
compared to those with no/low cough and phlegm (p<.0001). Four and greater 
exacerbations per year were reported by 25.9% of patients with moderate to high cough 
and 27.1% with moderate to high phlegm compared to those with no/low severity levels 
of cough and phlegm (11.0% for both).  
Cough and phlegm severity levels at baseline were strongly and positively 
correlated with presence or absence of cough or phlegm for at least three months per year 
in the past two years (τb = 0.607, p = 0.01). Among those respondents who reported 
bringing up phlegm from their chest at least three months per year in the past 2 years 
(68.5%), 87.1% had moderate/high phlegm levels. Similarly, of those who reported 
having cough for at least three months per year in the past 2 years (63.1%), 92.7% had 
moderate/high cough levels. 
There was a strong, positive correlation between cough and phlegm levels as 
measured by Kendall's tau-b, which was statistically significant (τb = 0.599, p < 0.01) 
(Table 3.2). Joint effects of cough and phlegm severity levels were, therefore, an 
appropriate measure of combining the severity of these two symptoms. Over 60% of the 
patients had moderate to severe levels of both cough and phlegm (62.0%), and 21.1% had 
no or low severity of both cough and phlegm. The remaining 16.9% of the study sample 
had combinations of no/low and moderate/high levels of each of the symptoms. 
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A total of 4,752 patients had complete data on all items in seven domains of 
PROMIS-29 and were included in the analyses of quality of life. Analysis of missing data 
(n=534, 10.1%) did not reveal any obvious patterns. Pearson correlations among the 
seven domains of PROMIS-29 were significant (p<.0001) and ranged from r = -0.27 to 
r = 0.77. The strongest correlations were identified between Physical Function and 
Ability to Participate in Social Roles and Activities (r=0.77, p<.0001), Anxiety and 
Depression (r=0.75, p<.0001), and Fatigue and Ability to participate in social roles and 
activities (r=-0.67, p<.0001) (Table 3.3). 
Mean scores of PROMIS-29 domains differed by levels of severity of cough and 
phlegm (p<.0001) (Table 3.4). Figure 3.3 demonstrates the burden of severity of cough 
and phlegm on patients’ quality of life in relation to the average scores for the general US 
population within the seven domains of PROMIS-29 (mean=50, SD=10). Anxiety, 
depression, fatigue, sleep disturbance, and pain interference scores increased in a 
stepwise fashion as the severity levels of cough and phlegm increased from no/low to 
moderate and high. Scores for these domains were on average one standard deviation 
higher in patients with high cough and phlegm compared to the standard US population. 
Similarly, scores for positively worded domains, such as Physical Function and Ability to 
Participate in Social Roles and Activities decreased as the severity of cough and phlegm 
increased. Patients with high levels of cough and phlegm scored on average 1 to 1.5 
standard deviations lower on these domains compared to the average US population. 
The results of the one-way multivariate analysis of variance (MANOVA)79 
identified significant mean differences between the joint levels of cough and phlegm and 
standardized scores of the seven PROMIS-29 domains (Pillai’s Trace=0.12, F (21, 
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14232) =27.96, p<.0001). Follow-up one-way ANOVAs on each of the seven dependent 
variables were performed, and all were found to be statistically significant (p<.0001). A 
series of post-hoc tests (Fisher’s Least Significant Difference (LSD)) were conducted to 
assess individual mean difference comparisons across the four levels of the joint cough 
and phlegm severity levels and all seven PROMIS-29 domains. The results were 
significant at the 0.0001 level except for no significant difference in Physical Functioning 
and Social ability scores between groups with moderate to high levels of both cough and 
phlegm and a group with low or no cough and moderate to high levels of phlegm. 
Additionally, no significant difference in Anxiety, Depression and Fatigue scores were 
found between no or low cough/moderate or high phlegm, and moderate or high cough/ 
no or low phlegm categories.  
Adjusted association between severity levels of both cough and phlegm and 
PROMIS-29 scores from all seven domains were significant controlling for age, gender 
and smoking history (Pillai’s Trace=0.12, F (21, 13974) =26.91, p<.0001). 
Overall, 2,696 participants qualified for the annual follow-up and 869 (32.2%) of 
them completed the follow-up survey. Of those, 863 had data on cough and phlegm 
severity, and 803 had complete data on PROMIS-29 and were included in the 
longitudinal analysis. At baseline, the majority of these patients reported moderate/high 
levels of cough and phlegm (66.9% and 64.4%, respectively), and only 33.1% and 35.6% 
reported no or low levels of cough and phlegm, respectively. At follow-up survey 
completion, 12.8-12.0% reported improved cough or phlegm and 9.3-10.2% reported 
worsened cough or phlegm (Table 3.5). The majority of the patients continued having 
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moderate/high levels of cough (54.1%) and phlegm (52.3%), and approximately a quarter 
of the participants still had no/low cough (23.8%) or phlegm (25.4%).  
Figure 3.4 demonstrates PROMIS-29 scores at follow up by severity changes in 
cough and phlegm between baseline and follow-up in relation to the average scores for 
the general US population within the seven domains of PROMIS-29 (mean=50, 
(SD=10)). Patients who continued having moderate to high severity levels of cough and 
phlegm reported having approximately half of a standard deviation greater scores for 
anxiety, fatigue, depression, pain interference followed by patients whose levels 
worsened from being no/low at baseline to moderate/high at follow-up. Scores for 
physical function and social ability at follow-up were significantly lower for those who 
continued having moderate to high severity levels of cough and phlegm and those whose 
cough and phlegm worsened, compared to patients with lessened severity or remaining 
with no/low cough and phlegm. Physical function scores were one standard deviation or  
greater than average scores for US population among all severity levels. 
PROMIS-29 domains scores at follow-up were significantly associated with 
changes in cough and phlegm severity over time. The results of the one-way MANOVA 
identified significant mean differences (one or more) between the cough severity changes 
and standardized scores of the seven PROMIS-29 domains (Pillai’s Trace=0.16, F (21, 
2385) =6.54, p<.0001). MANOVAs between the phlegm severity changes and seven 
PROMIS-29 domain scores demonstrated similar results (Pillai’s Trace=0.09, F (21, 
2385) =3.68, p<.0001). Follow-up one-way ANOVAs on each of the seven dependent 
variables were found to be statistically significant (cough severity changes: p<.0001 for 
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all domains, phlegm severity changes: p=0.0061 for depression, p<0.001 for anxiety and 
p<.0001 for all other domains). 
Missing data analyses compared select baseline characteristics of those patients 
who qualified for one year follow-up and completed the survey (“responders”, n=869) 
and those who qualified but did not respond to the invitation (“non-responders”, 
n=1,827). The “responders” were on average three years older (64.7 years vs 61.5 years), 
greater proportion of them were males (44.1% vs 32.2%, p<0.001), married (55.3% vs 
49.7%, p<0.001), had college degree or higher (42.8% vs 32.1%), reported no or low 
levels of phlegm (35.3% vs 30.7%, p=0.02) or cough (32.6% vs 25.6%, p<0.001). 
Additionally, we compared select baseline characteristics of the participants included in 
the follow-up analyses to those of the rest of the patients in the baseline cohort with 
similar findings except for no significant difference in mean age. 
3.4 Discussion 
This study of the association between severity of cough and phlegm and patient-
reported outcomes in   individuals within COPD PPRN community who self-reported 
physician-diagnosed COPD yields several important findings. First, the burden of cough 
and phlegm was high, with approximately three-quarters of the patients reporting 
moderate to high levels of cough and/or phlegm. Our findings support previously 
reported data on the frequency of cough (70%) and phlegm (60%) in patients with COPD 
in a large international survey.64,80  Recent Global initiative for chronic Obstructive Lung 
Disease (GOLD) statement acknowledged that cough and sputum production in the 
40 
 
COPD population may be underreported.81 This further underlines the importance of 
symptom burden estimates based on patient-reported data.  
Previous research related to the burden of cough and phlegm on patients’ health 
outcomes and their quality of life is limited.64  In earlier work, the major focus on cough 
and phlegm was to define chronic bronchitis, which specifically uses frequent and 
persistent cough and sputum production to define the phenotype.82-84 A pan-European 
study highlighted the importance of patient-perceived daily variability of the symptoms 
and related impact on quality of life and activities.85 The results of this study showed that 
overall COPD symptoms are most troublesome in the mornings compared to other times 
of the day. Specifically, among other symptoms, the greatest proportion of patients 
reported morning difficulties with cough (60.1%) and phlegm (70.9%). Washing and 
dressing were among the most affected by their symptoms morning activities reported by 
the study participants (41.0% and 40.7% respectively). Moreover, other researchers 
suggested that COPD patients with early-morning and nighttime symptoms are 
significantly more likely to have worse HRQOL.82,86,87 
Lindberg et al. in their recent work indicated that productive cough in patients 
with COPD was associated with exacerbations and risk for death.88 Previous work also 
identified cough to be significantly associated with decline in patients with airflow 
obstruction and independently associated with disability in COPD.64 In a large 
longitudinal study of Danish men, cough was found to have the highest predictive value 
for subsequent hospitalization due to pulmonary disease, and for treatment for airflow 
obstruction.89 Narrowing the focus to cough and phlegm particularly is important since 
currently only a few pharmacotherapies directly address either of these symptoms.63,81   
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In their recent narrative review, Miravitlles and Ribera described the impact of 
COPD symptoms on disease burden and HRQOL of the patients.82 They highlighted the 
association between burden of COPD symptoms and high levels of anxiety and 
depression as well as greater risk of exacerbations and worse patient outcomes. However, 
they did not specifically focus on cough and phlegm, and association between these 
symptoms and patients’ functional status, and other various aspects of quality of life. Our 
study findings indicate significant association between severity of cough and phlegm and 
patient-reported quality of life as measured by PROMIS-29. In our study cohort, 
increased cough and phlegm levels were associated with higher levels of fatigue, anxiety, 
and depression, greater pain interference and sleep disturbance, and lower social abilities 
and physical function.   
The NIH-developed PROMIS-29 has been shown to be a valuable instrument to 
assess several domains of quality of life across a range of chronic morbidities and various 
clinical populations.77,90 In 2009, a longitudinal study assessed the validity of PROMIS 
with COPD exacerbations, and evaluated responsiveness of the instrument with a known 
change in the underlying COPD, i.e., acute and stable conditions.91 Recent study by Irwin 
et al. examined the performance of PROMIS instrument in patients with COPD according 
to their exacerbation status.92 It has identified that stable patients had significantly better 
PROMIS scores in all domains. Similarly to our study, study by Irwin et al. used self-
reported COPD status and did not include other clinical assessments.92  
Findings of a multi-center cross-sectional study (CONCERT) supported the 
validity of PROMIS in patients with COPD and identified that among all domains, 
physical functioning was most negatively affected compared to the general population 
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across all COPD severity grades.93 Consistent with these findings, our study results also 
indicate the worst standardized scores in Physical Function (over 1 SD worse than the 
average scores for the general US population) among all seven PROMIS-29 domains 
across all cough and phlegm severity levels.  
Recent research by Schalet et al. evaluated longitudinal performance of Physical 
Function domain of PROMIS in six chronic health conditions including COPD.94 No 
significant change in physical function over time was detected in patients with COPD 
exacerbations which may be attributed to only minor improvements in physical function 
during 12 weeks of follow-up and considerably small sample size of subgroups (under 20 
patients).94 In the longitudinal portion of our study, patient-reported improvements in 
cough and phlegm severity over time (improved scores on those questions in the CAT) 
was associated with better quality of life at the follow-up timepoint as measured by 
PROMIS-29. 
The significance of patient-reported outcomes and particularly PROMIS-29 in 
comparative effectiveness research was highlighted in the recent research by Craig et al.95 
The authors identify the importance of patient-reported outcomes in assessing cost-
effectiveness of various treatment options.95 The findings of our study highlight the needs 
to review and renew the search for therapies designed to reduce either cough or phlegm.   
No new and effective cough medication has been developed by the pharmaceutical 
industry in over a century.64 Only about a third of the patients in our study had either no 
or low severity of cough or phlegm.  Higher severity of cough and phlegm were found to 
be associated with worse mood, pain, sleep, and physical and social functioning.  The 
levels of cough and phlegm might also be explored as a proxy for COPD disease severity. 
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The consistent association between high levels of cough and phlegm burden and worse 
quality of life suggests the need for further research in this area. 
Strengths and Limitations 
The main strengths of our study include a large number of patients enrolled in the 
COPD PPRN as well as unique and rich data collected by the COPD PPRN. These data 
include seldom-addressed patient-reported outcomes such as patient-perceived ability to 
participate in social roles and activities, physical function, anxiety, depression, and sleep 
disturbance. Some of the limitations of the study include potential selection bias in view 
of the self-reported nature of physician-diagnosed COPD. Patient-reported clinical 
information including presence of comorbidities, frequency of physician, ER visits and 
hospitalizations are subject to potential recall bias. Also, classification of cough and 
phlegm severity levels for the purposes of this study was performed according to the 
respective CAT scores and is not a widely used classification.  Additionally, many 
participants were excluded from the follow-up analyses due to not qualifying, not 
responding to the follow-up survey or missing data. Missing data analysis identified that 
those included in the follow-up analyses differed from those excluded in several 
demographic and clinical characteristics that may have introduced potential selection 
bias. 
3.5 Conclusion 
In this population of people with self-reported physician-diagnosed COPD, 
severity of cough and phlegm are associated with higher number of exacerbations, greater 
dyspnea, and worsened patient-reported quality of life including physical and social 
functioning. Improvement in cough and phlegm severity over time is associated with 
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improvement of patient-reported quality of life. Further work in this area is needed 
including exploration of new treatments aimed at improvement of cough and phlegm 
severity in this patient population. 
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Table 3.1  Select demographic and clinical characteristics of the study participants, n = 5,286    





 No/ Low  
(CAT 0-1) 
N = 1,699 
(32.1%) 
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(67.9%) 
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BMI, mean (SD) 28.2 (7.6)  28.0 (7.1) 28.5 (7.7)  27.4 (6.7) 28.7 (7.8) 
Never smoker, n (%) 620 (11.7)  230 (13.6)‡ 390 (10.9)‡  153 (10.8) 467 (12.1) 
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(32.1%) 
Moderate/ High
 (CAT 2-5) 
N= 3,587 
(67.9%) 
 No/ Low 
(CAT 0-1) 




N = 3,862 
(73.1%) 
History of cough for at 
least 3 months per year for 




























History of phlegm for at 
least 3 months per year for 




































     
 
1,114 ( 78.2) 



























Table 3.1   Continued 
†p<0.0001; ‡p<0.001; *- Other races include Native Hawaiian/Pacific Islander and American Indian/ Alaska Native; **-defined as a 
max number of antibiotic/prednisone/ER visit/ hospital, CACI- Charlson Age-Comorbidity Index, mMRC- (Modified Medical 
Research Council) Dyspnea Scale 
mMRC***: 
0: "I only get breathless with strenuous exercise" 
1: "I get short of breath when hurrying on the level or walking up a slight hill" 
2: "I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my 
own pace on the level" 
3: "I stop for breath after walking about 100 yards or after a few minutes on the level" 





 Table 3.2  Cross-tabulation of cough and phlegm severity categories, n=5,286 
Cough Categories 
Phlegm Categories 
High Moderate No/Low 
High 708 (64.1) 498 (20.1) 48 (2.8) 
Moderate 365 (33.0) 1,706 (68.7) 537 (31.6) 
No/Low 32 (2.9) 278 (11.2) 1,114 (65.6) 
Note: τb = 0.599, p < 0.01 
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Table 3.3  Pearson correlations, means and standard deviations associated with the 
PROMIS-29 domains, n=4,752 




1.0       37.14 7.33 
Social 
Ability 
0.77 1.0      42.78 9.13 
Sleep 
Disturbance 
-0.27 -0.36 1.0     52.55 8.88 
Anxiety -0.36 -0.47 0.43 1.0    56.10 10.34 
Depression -0.39 -0.51 0.41 0.75 1.0   54.66 10.09 
Fatigue -0.57 -0.67 0.50 0.54 0.59 1.0  57.11 9.79 
Pain 
Interference 
-0.35 -0.43 0.43 0.42 0.42 0.51 1.0 54.33 10.83 
Note: all correlations were statistically significant, p<.0001; PF-Physical Function; SA- 
Social Ability; SD-Sleep Disturbance; AN- Anxiety; DE-depression;  FA- Fatigue; PI- 




































Physical Function 37.1 (7.3) 39.6 (8.2) 36.6 (6.7) 34.4 (6.0) 39.3 (8.3) 36.9 (7.0) 35.1 (6.2) 
Ability to 
Participate in Social 
Roles and Activities 
42.8 (9.1) 45.8 (9.9) 42.3 (8.4) 39.2 (7.9) 45.4 (10.0) 42.7 (8.7) 40.0 (8.0) 
Sleep Disturbance 52.5 (8.9) 49.8 (8.6) 52.8 (8.5) 56.1 (8.7) 49.1 (8.5) 52.4 (8.3) 56.7 (8.8) 
Anxiety 56.1 (10.3) 53.4 (10.0) 56.2 (10.2) 60.0 (10.0) 53.3 (9.9) 56.0 (10.0) 59.5 (10.5) 
Depression 54.7 (10.1) 52.3 (9.7) 54.6 (9.7) 58.4 (10.3) 52.2 (9.7) 54.3 (9.7) 58.1 (10.4) 
Fatigue 57.1 (9.8) 53.6 (10.0) 57.6 (9.1) 61.5 (8.9) 53.3 (10.2) 57.1 (8.9) 61.4 (9.4) 
Pain Interference 54.3 (10.8) 51.2 (10.3) 54.7 (10.6) 58.1 (10.8) 50.3 (10.0) 54.4 (10.5) 58.6 (10.8) 
Note: All statistics are reported as mean (SD) unless otherwise indicated. For negatively worded concepts -Sleep Disturbance, 
Anxiety, Depression, Fatigue and Pain Interference- higher PROMIS-29 T-score (above 50) reflects worse outcome. For positively 
worded concepts -Physical Function and Ability to Participate in Social Roles and Activities- higher PROMIS-29 T-score (above 50) 
reflects better outcome. 
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Table 3.5  Changes in severity levels of cough and phlegm between baseline and follow-
up, n=803 
 Cough Phlegm 
Improved (Mod/High to No/Low) 103 (12.8) 97 (12.1) 
Remained Mod/High 434 (54.1) 420 (52.3) 
Remained No/Low 191 (23.8) 204 (25.4) 
Worsened (No/Low to Mod/High) 75 (9.3) 82 (10.2) 
Note: All statistics are reported as n (%) 
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Figure 3.3  PROMIS-29 T-scores at baseline by severity of cough and phlegm, n=4,752 
 
Note: PROMIS-29 T-scores above 50 (average for the US population) indicate worse outcomes for Anxiety, 









Figure 3.4 . PROMIS-29 T-scores at follow-up by severity changes in cough and phlegm between baseline and follow-up, n=803 
 
 
Note: PROMIS-29 T-scores above 50 (average for the US population) indicate worse outcomes for Anxiety, 






CHAPTER 4. PSEUDOMONAS AERUGINOSA ASSOCIATED WITH SEVERITY 
OF NON-CYSTIC FIBROSIS BRONCHIECTASIS MEASURED BY THE 
BRONCHIECTASIS SEVERITY SCORE (BSI) AND THE FACED: THE US 
BRONCHIECTASIS AND NTM RESEARCH REGISTRY (BRR) STUDY  
Abstract 
Rationale: Non-cystic fibrosis bronchiectasis (NCFB) is characterized by dilated 
bronchi, poor mucus clearance and susceptibility to bacterial infection. Pseudomonas 
aeruginosa (PA) is one of the most frequently isolated pathogens in patients with NCFB. 
The purpose of the present study was to evaluate the association between presence of PA 
and disease severity in patients with NCFB within the US Bronchiectasis and 
Nontuberculous mycobacteria (NTM) Research Registry (BRR). 
Methods: Baseline US BRR data from adult patients with NCFB collected between 2008 
and 2018 was used for this study. Presence of PA was defined as one or more, and 
chronic colonization as two or more positive PA cultures within two years prior to 
enrollment. Descriptive statistics were computed for the overall study sample and 
stratified by presence of PA. Values between the strata were compared using t-tests for 
continuous variables, and Chi-square tests for categorical variables. Modified 
Bronchiectasis Severity Index (m-BSI) and modified FACED (m-FACED) were 
computed to evaluate severity of bronchiectasis. Unadjusted and multivariable 
multinomial regression models were used to assess the association between presence of 
PA and severity of bronchiectasis.  
Results: Average age of the study participants (n=1,831) was 63.7 years (SD=14.1), 
91.5% white, 78.8% female, 41.0% reported history of smoking, and 48.3% had history 
of NTM. Presence of PA was identified in 25.4%, and chronic colonization in 13.6% of 
the patients. Patients with presence of PA had significantly lower mean pre-
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bronchodilator Forced Expiratory Volume in the first second (FEV1) % predicted 
compared to those without PA (62.8% vs. 73.7%, p<.0001). In multivariate analyses, 
patients in PA group had significantly greater odds for having high (ORadj=6.41 (95%CI: 
4.15-9.89) and intermediate (ORadj=2.11 (95%CI: 1.40-3.16) severity vs. low severity on 
m-BSI. The sensitivity analyses after excluding PA severity marker from calculation of 
m-BSI and m-FACED showed the same direction of the association as in the main 
analyses. 
Conclusion: PA infection is common in patients with NCFB within the Bronchiectasis 
and NTM Research Registry. Severity of bronchiectasis is significantly greater in patients 
with PA which emphasizes high burden of the disease. Future longitudinal studies are 
recommended to assess clinical outcomes and prognosis over time. 
 
4.1 Introduction 
Non-cystic fibrosis bronchiectasis (NCFB) is an etiologically diverse, irreversible, 
and chronic disease associated with significant morbidity in adults.22,24 NCFB is 
characterized by dilated bronchi, poor mucus clearance and susceptibility to bacterial 
infection leading to productive cough, recurrent infections, and exacerbations.96,97 
Prevalence of NCFB in the United States is increasing, especially with age, and has been 
estimated between 230,000 and 430,000 cases using three large US healthcare 
databases.98 Bronchiectasis was shown to be more expensive to treat compared to many 
other chronic diseases.99 Annual burden of bronchiectasis to the healthcare system has 
been estimated at approximately $630 million.97  
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According to the “vicious circle” theory of bronchiectasis pathogenesis, airway 
inflammation in response to pulmonary infection results in airway damage, mucus 
collection, and further infections.24,79 Among the most prevalent gram-negative bacteria 
responsible for pulmonary infections in patients with NCFB, Pseudomonas aeruginosa 
(PA), an opportunistic pathogen, possesses natural resistance to antibiotics that makes 
these infections particularly challenging to treat.100 PA colonization is associated with 
worse lung function, higher mortality, hospitalizations, exacerbations, and decreased 
quality of life.24,101 To date it remains unclear whether infection with PA is the result or 
the cause of severe NCFB.102 
The overall significance of PA in the natural course of bronchiectasis has been 
reflected by inclusion of PA as a key marker in the calculation of several severity 
assessment instruments. The Bronchiectasis Severity Index (BSI) is a disease-specific 
clinical predictive tool derived in the United Kingdom and validated in several European 
cohorts.25 This instrument was designed to identify bronchiectasis patients with future 
risk for mortality, hospitalizations, exacerbations, and poor quality of life.25 
Independently, Spanish researchers derived another severity assessment tool, FACED, 
which utilizes only five dichotomized variables in its calculation and was validated for 5-
year mortality.26  
A wide range of NCFB and PA management strategies exists among clinicians 
both in the US and internationally, which highlights the need and importance of 
collaborative research to improve patient outcomes.96 Findings from bronchiectasis 
registry-based studies assist in guiding future clinical trials to enhance treatment options 
in this patient population. 
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The two main objectives of the present study were to estimate the prevalence of 
PA and to evaluate the association between the PA and disease severity measured by the 




This study used baseline data from the Bronchiectasis and NTM Research 
Registry (BRR). The BRR is a centralized database of adult patients with physician-
diagnosed NCFB or NTM from 16 clinical institutions across the United States.103 After 
obtaining informed consent, patients’ medical records are queried by trained site study 
coordinators using standardized data collection forms. Data collection includes 
demographic information, medical history and procedures, respiratory symptoms, 
therapies and treatment, imaging, microbiology results, and other detailed clinical 
information. Data entry is done through a centralized Internet-based entry system 
managed by the data coordinating center. At the time of enrollment, patients with primary 
Cystic Fibrosis bronchiectasis are excluded based on clinical history, previous sweat 
chloride or genetic testing results. After enrollment, follow-up data is collected annually 
from participants’ electronic medical records as it becomes available. As of October 
2018, the BRR contained data on over 3,000 patients with up to 10 years of participant 
follow-up. BRR obtains institutional review board (IRB) approvals for each BRR 
participating site.  
Baseline data utilized in the present study included data abstracted from patients’ 
records during the registry baseline period, which is defined as the interval between the 
61 
 
two years prior to and 90 days after patients’ enrollment.103 Microbiological evaluation at 
baseline consisted of a maximum of three respiratory culture results for each of the 
bacterial, fungal and mycobacterial growth. Bacterial cultures included available data on 
numerous microorganisms such as PA, Haemophilus influenza, Staphylococcus aureus, 
and other pathogens. For the purposes of the present study, “presence” of a 
microorganism was defined as one or more, and “chronic colonization” as two or more 
positive cultures available at baseline. Patients with presence of PA at baseline were 
identified as a “PA group,” and those without presence of PA at baseline as a “non-PA 
group.” NTM status of patients in this study was defined as a reported history of NTMLD 
prior to enrollment or one or more NTM positive cultures within the baseline period, or 
both.103 Baseline data also contained information on number of hospital admissions and 
exacerbations within the preceding two years prior to enrollment.  
Severity of bronchiectasis was evaluated using the BSI, which was derived and 
validated in the United Kingdom to identify bronchiectasis patients with future risk of 
mortality, hospitalizations, exacerbations, and poor quality of life.25 The BSI is a 
multidimensional instrument that consists of nine severity markers that have been 
identified by the authors as common variables that predict mortality and 
hospitalizations.25 These severity markers include age, BMI, Forced Expiratory Volume 
in the first second (FEV1) % predicted, prior hospitalizations, history of exacerbations in 
the previous year, Medical Research Council (MRC) dyspnea score, PA colonization, 
colonization with other microorganisms, and radiological severity. For the purposes of 
the present study, the BSI was modified according to the structure of the BRR data 
collection, and modified BSI (m-BSI) was computed to evaluate the severity of NCFB. 
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Specifically, modifications to the BSI were made to accommodate alternate measurement 
of dyspnea in the BRR data collection forms that identifies presence or absence of 
dyspnea when active or when at rest. The original BSI uses the MRC dyspnea scale that 
rates patients’ perception of dyspnea severity on a 1-5 Likert-type scale.73,104 In addition, 
BRR collects data on frequency of exacerbations and hospitalizations in the previous two 
years at enrollment, and the BSI measures frequency of these markers in the past one year 
(Table 4.2). Using the BSI scoring guidelines, the m-BSI (range 0-26 points) scores were 
derived as sums of the score points for each of the nine severity markers. Using the same 
guidelines, the patients were classified into three bronchiectasis severity categories 
according to the total m-BSI score value: 1) low, 0-4 points, 2) intermediate, 5-8 points, 
and 3) high, 9 or more points.  
FACED, our second bronchiectasis severity assessment instrument, was derived 
and validated by Spanish researchers independently from the BSI.26 It utilizes only five 
dichotomized variables in the calculation the severity score- FEV1 % predicted, Age, 
Chronic colonization, Extension (radiological), and Dyspnea. Similar to the BSI, this 
instrument was also modified to accommodate the alternate dyspnea measurement scale 
and modified FACED (m-FACED) was calculated for study participants (Table 4.3). The 
m-FACED (range 0-7 points) was computed as a sum of the score points for each of the 
five dichotomized variables. According to the FACED scoring guidelines, bronchiectasis 
was classified into three severity classes according to the total m-FACED score: 1) mild, 





Descriptive statistics were computed for the overall study sample and stratified by 
presence of PA at baseline.  All results were reported as frequencies and proportions for 
categorical variables, and as means (± SD) for continuous variables. m-BSI and m-
FACED severity levels were calculated for the overall cohort and analyzed stratified by 
PA presence at baseline. Values between the strata were compared using t-tests for 
continuous variables, and Chi-square tests for categorical variables. To assess the 
influence of the variable identifying chronic colonization by PA on the severity of 
bronchiectasis, m-BSI and m-FACED were also computed after excluding chronic 
colonization by PA from the severity markers. 
Ordinal regression models were initially considered for the analyses, but the 
proportional odds assumption assessed using score test was found not to be supported by 
the data for either m-BSI or m-FACED: m-BSI: χ2 (DF=6) = 43.46, p <.0001; m-FACED: 
χ2 (DF=5) = 59.81, p <.0001). Thus, multinomial logistic regression models were used to 
examine the association between presence of PA and severity categories of bronchiectasis 
on m-BSI and m-FACED.  Both unadjusted and adjusted results were obtained. In the 
adjusted regression models, we controlled for variables that had clinical importance, 
statistically significant difference between the PA groups in the bivariate analyses, and 
either not included in the calculation of severity indices or used in a different form. The 
final models included age as a continuous variable, gender, NTM status, and FEV1 % 
predicted as a continuous variable. 
Sensitivity analyses were performed by excluding the PA severity item from the m-BSI 
and m-FACED scoring prior to fitting multinomial regression models. Cohen’s kappa 
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statistic was used to measure the agreement between the m-BSI and FACED severity 
classification. Missing data analyses compared the included study population with those 
who were excluded from the analyses due to missing or incomplete data. Significance 
level was set at 0.05. Statistical analyses were performed using SAS version 9.4. 
 
4.3 Results 
Of 3,008 participants in the BRR as of October 2018, 1,831 had data available on 
variables needed for calculation of m-BSI and m-FACED and were included in the 
present study. Demographic characteristics of the study population at baseline are 
displayed in Table 4.1. The average age of the study participants was 63.7 years 
(SD=14.1), 91.5% white, 78.8% female, 41.0% reported history of smoking. Presence of 
PA was identified in 25.4%, and chronic colonization in 13.6%, of the patients.  
Patients in the PA group had significantly lower mean pre-bronchodilator FEV1% 
predicted (62.8% vs. 73.7%, p<.0001) and FVC% predicted (74.4% vs. 81.8%, p<.0001) 
compared to those without PA. A significantly greater proportion of patients with 
presence of PA at baseline reported three or more exacerbations (30.5%) and history of 
hospital admissions (32.0%) in the previous two years prior to enrollment compared to 
those without PA (17.2% and 17.1% respectively, p<.0001). Approximately half of the 
respondents (48.3%) had a history of NTM with significantly greater proportion among 
those in non-PA group (51.7% vs. 38.5%, p<.0001). There was no significant difference 
in age, race, ethnicity or smoking history between the two groups. 
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Tables 4.2 and 4.3 contain data on frequencies of individual components of m-
BSI and m-FACED in the overall study sample and stratified by PA group. Statistically 
significant differences were found between the PA groups in age, FEV1% predicted, 
hospital admissions, number of exacerbations, dyspnea, and radiological severity for m-
BSI (Table 4.2). Similarly, the two groups differed in FEV1% predicted, age, and 
dyspnea for m-FACED (Table 4.3). 
Table 4.4 demonstrates bronchiectasis severity categories using m-BSI and m-
FACED computed for the overall study sample and stratified by presence of PA at 
baseline. According to m-BSI, a majority of the respondents were classified as 
intermediate (41.2%) and high (35.5%) severity of bronchiectasis. In comparison, m-
FACED classified over half of the patients (52.5%) as mild disease severity, followed by 
moderate (37.4%) and high severity (10.1%) of bronchiectasis. Table 4.5 demonstrates 
comparison of bronchiectasis severity classification by both instruments and agreement 
rates (kappa= 0.2632 (95% CI: 0.2334-0.2930)). There was fair agreement between the 
two instruments in classifying severity of NCFB.105 
For disease severity, a significantly greater proportion of patients with PA were 
classified as having high severity of bronchiectasis using both m-BSI (60.9% vs. 26.9%, 
p<.0001) and m-FACED (25.8% vs. 4.8%, p<.0001) compared to those without PA. 
Likewise, both m-BSI and m-FACED classified greater proportion of patients without PA 
as having low and mild severity of the disease (m-BSI: 27.9% vs. 9.7%, m-FACED: 
58.9% vs. 33.8%, p<.0001) (Figure 1).   
Table 4.4 presents the results of the sensitivity analyses demonstrating the 
distribution of the m-BSI and m-FACED severity categories after excluding PA severity 
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marker from the scores’ calculations. Removing chronic colonization by PA variable, that 
is weighted as 3 points in the calculation of the m-BSI and 1 point in m-FACED, resulted 
in a greater proportion of the participants to be re-classified as low or moderate severity 
by m-BSI and m-FACED. We compared disease severity between the PA strata after 
removing PA variable from the scores’ calculations. The proportion of PA-positive 
patients who were classified as high severity of bronchiectasis on m-BSI and FACED 
remained significantly greater compared to those without PA (m-BSI: 45.8% vs. 26.9%, 
p<.0001; m-FACED: 11.8% vs. 4.8%, p<.0001). 
Results of the unadjusted and adjusted multinomial regression models are 
presented in Table 4.6. The multinomial regression estimated the log-odds: 1) comparing 
high severity of bronchiectasis vs low, and 2) comparing intermediate severity vs low. 
First, we fit the unadjusted multinomial regression model with m-BSI as an outcome 
variable. Patients in PA group had 6.53 times the odds for having high severity vs. low 
(95% CI: 4.62-9.23), and 1.88 times the odds for having intermediate severity vs. low 
(95% CI: 1.31-2.69).  
The adjusted multinomial regression fit the two equations below, with each 
comparison having its own intercept and set of coefficients: 
1) Log (  ) = β0  + β1 (PA =1) + β2 (Age)+ β3(Female=1) + β4 (FEV1%predicted)+ 
β5 (Exacerbations in the past 2 years=1) + β6 (NTM history=1) 
 
2) Log (  ) = β0*  + β1* (PA =1) + β2* (Age)+ β3* (Female=1) + β4* 
(FEV1%predicted)+ β5* (Exacerbations in the past 2 years=1) + β6* (NTM history=1)  
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Results of the adjusted multinomial regression model are presented in Table 4.6. 
Controlling for other covariates in the model, participants in PA group had 6.15 times the 
odds of being classified as high severity of bronchiectasis versus low severity on m-BSI 
(95% CI 3.98-9.50), and 2.06 times the odds of being classified as intermediate severity 
of bronchiectasis versus low severity on m-BSI (95% CI 1.37-3.09). 
Similarly, we found a significant association between presence of PA at baseline 
and severity of bronchiectasis calculated using m-FACED. Table 4.6 presents the results 
of unadjusted and adjusted multinomial regressions using m-FACED as an outcome 
variable. In unadjusted analyses, participants with PA had 9.47 times the odds (95% CI: 
6.69-13.39) for having severe bronchiectasis on m-FACED versus mild, and 1.94 times 
the odds (95% CI: 1.53-2.47) for having moderate bronchiectasis vs. mild. 
Results of the adjusted analyses demonstrated that controlling for other covariates 
in the model, the participants with PA had 14.59 times the odds (95% CI: 8.53-24.94) for 
having severe bronchiectasis versus low, and 2.15 times the odds (95% CI: 1.59-2.91) for 
having moderate bronchiectasis vs. mild.  
Results of the sensitivity analyses after excluding PA severity marker from 
calculation of m-BSI and m-FACED showed the same direction of the association as in 
the main analyses, although the effect size was attenuated in unadjusted analyses and 
failed to reach statistical significance at α=0.05 in most adjusted analyses for both m-BSI 
and m-FACED (Table 4.6). 
Missing data analyses did not reveal any significant differences between the 
patients included in the present study and those excluded from the analyses due to 
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incomplete data in gender, ethnicity, and smoking status. However, we identified a 
greater proportion of white patients among those included in the study (91.53% vs. 
88.81%, p=0.02). In addition, our study participants were on average over two years 
younger (63.7 vs. 66.0 years, p<.0001), and had lower FEV1%predicted (70.9 (±22.2) vs. 
77.7 (±21.6), p<.0001) and FVC % predicted (79.9 (±19.7) vs. 87.6 (±20.2), p<.0001) 
compared to excluded patients. 
4.4 Discussion 
Our study of patients with NCFB utilizes baseline data from the BRR (n=1831) to 
assess the prevalence of PA presence in sputum of patients with NCFB and evaluates the 
association between the presence of PA and disease severity using two bronchiectasis 
severity assessment instruments.  
Our analyses indicate that over a quarter of patients in our study (25.4%) showed 
presence of PA in their sputum culture at baseline, and 13.6 % of the participants had 
chronic colonization by PA. This is in agreement with previously reported PA prevalence 
in the earlier BRR cohort103 as well as other studies of patients with NCFB including a 
Spanish cohort with 19.7% of patients with chronic PA colonization.106 Our findings also 
support the recent report of chronic PA infection in 15% of patients within the European  
FRIENDS bronchiectasis cohort.107 Notably, the lower prevalence of PA presence of only 
12% was reported by researchers in a longitudinal study in Australia.108 Significantly 
higher prevalence of PA presence (47%) and colonization (30%) were reported by 
authors of a recent study in England.109 The authors suggest that the high prevalence of 




Our review of reported PA prevalence in various bronchiectasis cohorts reflects a 
wide variety of prevalence estimates of presence as well as chronic colonization of PA in 
patients with NCFB in different geographic areas. In some cohorts, including our study 
population, PA is identified as the most prevalent microorganism103 while others report  
Haemophilus influenza was the most prevalent pathogen.108,110 Identification of prevalent 
microorganisms and treatment selection according to the culture results is highly 
important in patients with NCFB. According to the vicious cycle hypothesis, pathogenic 
microorganisms such as PA may potentially play a role in the development of 
bronchiectasis.24,79 Hence, early identification of PA presence and prevention when 
possible as well as the timely start of appropriate antibacterial therapy are highly 
recommended in patients with bronchiectasis.111  
We observed that almost a third of the patients in the PA group reported having 
three or more exacerbations in the past two years compared to only 17.1% of those 
without presence of PA. Similar finding have been previously reported in the European 
cohort of patients with bronchiectasis by Chalmers et al.112 In their recently published 
research, the authors identified that patients with chronic PA infection had over two times 
the odds for having three or more exacerbations at follow-up even when they had less 
than three exacerbations at baseline. Rogers et al. in their recent study highlighted that 
presence of PA in sputum of patients with bronchiectasis was the best predictor of future 
exacerbations.113 Chalmers et al. established a “frequent exacerbator phenotype” among 
patients with NCFB that reflects that prior exacerbations in these patients predict future 
risk for exacerbations.112 Considering that exacerbations are frequently associated with 
bacterial infections, and PA is one of the most prevalent microorganisms in patients with 
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NCFB, it is critical to recognize the importance of timely identification of PA in sputum 
which has important management and prognostic implications in this patient 
population.24,114 
Our study findings indicate that patients with presence of PA have worse 
pulmonary function compared to those without. This supports earlier research by Evans 
et al. that chronic colonization by PA is associated with worse lung function including 
lower FEV1 and FVC %predicted than in patients without PA.102 The authors suggest 
that PA colonization takes place in patients with already rapidly declining lung function 
and additionally accelerates the decline.102 This agrees with another study by Davies et al. 
that PA infection occurs in patients with more severely impaired lung function, however, 
PA colonization does not influence the rate of decline in pulmonary function over time.115  
Consistent with previous research, our study results suggest that the presence of 
PA infection in patients with NCFB is associated with high severity of disease and poor 
prognosis.24,102,116 Until recently, there were no bronchiectasis-specific severity 
assessment instruments that would assist in stratifying the risk for mortality, 
exacerbations, hospitalizations, and quality of life. Chalmers and colleagues derived and 
validated the BSI to identify high-risk patients with bronchiectasis and guide appropriate 
therapy and disease management options.25 A significantly greater proportion of patients 
with PA in our study were classified as high severity of disease on m-BSI compared to 
those without PA. We observed similar results using another bronchiectasis-specific tool, 
m-FACED, to stratify disease severity by PA presence. Of note, even presence of only 
one or more positive PA cultures in our study population was significantly associated 
with disease severity classification that utilizes PA chronic colonization as a predictor. 
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This suggests that patients with even only presence of PA may have considerably greater 
risks for poor prognosis. 
Our findings of fair agreement (kappa= 0.2632) between the m-BSI and m-
FACED in classifying the severity of NCFB support findings by researchers in Portugal. 
A study by Costa et al. compared the performance of the BSI and FACED and found a 
similar association between the scores (kappa=0.330, p=0.002).117 
Rosales-Mayor et al. recently compared the performance of the BSI and FACED 
within a Spanish cohort of patients with bronchiectasis, and concluded that these 
prognostic scores classified patients differently.118 The majority of patients in their study 
were classified as severe (54.4%) and moderate (25.8%) on BSI, and as mild (59.3%) and 
moderate (33.5%) on FACED. The authors highlighted that the BSI showed superior 
ability to predict future exacerbations within their cohort of patients compared to 
FACED, and suggested modifications to enhance the existing FACED by including an 
exacerbation severity marker.118  Similar to the research by Rosales-Mayor et al.118, our 
findings indicate that even after modifications made to the original instruments, m-BSI 
and m-FACED categorize severity of bronchiectasis in patients with NCFB differently, 
and distribution of severity categories in our study population is similar to the findings by 
Rosales-Mayor and colleagues. In our study, m-BSI stratified significantly higher number 
of patients into high severity group compared to m-FACED which suggests worse 
prognosis and high risk for poor outcomes. This might be related to the fact that FACED 
does not account for the number of exacerbations, a known important factor in 
identifying a future risk of the patients with NCFB. FACED has been validated for 5-year 
all-cause mortality risk and has not been validated for exacerbations.26  
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Wilson et al. showed that health-related quality of life (QoL) of patients with PA 
colonization was significantly worse compared to those with no PA using several 
standardized measures.116 Patients with PA in their study also had worse pulmonary 
function and greater disease severity on CT scans, although the authors suggest that 
exacerbation frequency and bacteriology were better correlates to QoL. The authors also 
highlighted the importance of breaking down the non-PA group into subcategories by the 
presence of other microorganisms.116 The QoL measures were not available in our data, 
although our study assessed and compared shortness of breath between the PA groups. A 
significantly greater proportion of patients with PA presence reported dyspnea when 
active and when at rest which may worsen their quality of life. 
High severity classification of patients with PA in our study suggest the 
importance of appropriate management considerations to improve prognosis in this 
patient population. Wilson and colleagues in their recent work highlighted the challenges 
associated with the treatment of NCFB patients with presence of PA.96 The most recent 
British Thoracic Society (BTS) guidelines for bronchiectasis in adults recommend using 
the BSI to help guide management of patients.119 Their updated stepwise management 
recommendations consider the underlying cause of NCFB and exacerbation frequency in 
treatment considerations. Wilson et al. underline the opportunities for PA management in 
patients with NCFB during the three timepoints: at first isolation, during exacerbations, 
and chronic PA colonization.96 The authors reflect on the importance of international 
collaborations in research into management strategies and development of new drugs for 
patients with this chronic disease, a discussion that took place during an expert forum 
held at the ERS in 2014.96 Renewed interest in NCFB, increase in research activity within 
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international bronchiectasis registries and needs for multidisciplinary approach to 
management of NCFB to improve patient outcomes were also highlighted at the recent 
World Bronchiectasis Conferences.23 
Strengths and Limitations 
Among the strengths of the present study, it is important to note the large number 
of patients with NCFB and NTMLD enrolled in the US BRR, as well as the exceptionally 
wide range of detailed data collected on clinical characteristics of the BRR cohort and 
patient outcomes. 
As with any registry-based observational study, our study has some limitations. 
The BRR participants are recruited from the tertiary referral institutions and may not be 
representative of the general population of patients with NCFB. Additionally, considering 
the high interest of these institutions in NTMLD, our study cohort may be enriched for 
patients with NTM. Geographic distribution of the referral medical facilities mainly 
represents large cities in the Eastern part of the US, which may have introduced a 
selection bias.  
The BRR contains data collected from multiple study sites. Our study did not 
account for potential differences in patient characteristics, the prevalence of 
microorganisms or comorbidities, or physician practices and treatment availabilities 
across the medical institutions. Also, patients within clinical sites might be similar and 
more correlated in their characteristics.  
Clinical data obtained using medical charts abstraction is often subject to 
recording errors and missing entries which may lead to reporting and non-response 
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biases. Although, the data management system has incorporated expected range checks to 
lessen potential data entry errors, and all study coordinators utilized the same 
standardized data collection forms.  
Another potential limitation is that our study modified the bronchiectasis severity 
scores to adapt to the BRR data collection. Although, the modifications were relatively 
minor and mainly related to a measure of dyspnea and time period of exacerbations and 
hospitalization frequencies. In addition, potential selection bias due to missing and 
incomplete data cannot be excluded. 
4.5 Conclusion 
PA infection is common in patients with NCFB within the BRR. The severity of 
bronchiectasis is significantly greater in patients with PA which emphasizes the high 
burden of the disease. Future longitudinal studies are recommended to assess clinical 
outcomes and prognosis over time. Further collaborative work in this area are needed 
including exploration of new management options aimed at the improvement of patient 
outcomes and prognosis in PA infected NCFB patients. 
Funding support: This study was sponsored by the COPD Foundation
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Table 4.1  Select baseline characteristics of the study population within the BRR 
stratified by presence of PA*, n=1,831 
 Overall 
N=1,831 
Presence of PA* 
N=465 (25.4%) 




Age, years, mean (SD) 63.7 (14.1) 64.4 (14.8) 63.5 (13.9) 
Female, n (%) † 1,443 (78.8) 350 (75.3) 1,093 (80.0) 
Race, n (%) 
White 



















Hispanic, n (%) 82 (4.5) 27 (5.8) 55 (4.0) 
















NTM-positive***, n (%) ‡ 885 (48.3) 179 (38.5) 706 (51.7) 
Pre-bronchodilator FEV1 















Three or more 
exacerbations within the 








History of hospital 
admissions within the past 







BRR- Bronchiectasis Research Registry; PA- Pseudomonas aeruginosa; NTM - 
Nontuberculous mycobacteria; FEV1- Forced Expiratory Volume in the first second; 
FVC- Forced vital capacity; *≥1cultures positive for PA at baseline, ** includes Native 
Hawaiian or Other Pacific Islander and American Indian or Alaska Native; ***- history 
of NTM or ≥1 cultures positive for NTM at baseline; †p<0.05, ‡p<0.0001
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Table 4.2  m-BSI severity markers distribution in the overall study sample and stratified 
by PA presence, n=1,831 
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Table 4.2  Continued     







































<3 lobes involved  

























m-BSI –modified Bronchiectasis Severity Index; BMI- Body Mass Index; FEV1- Forced 
Expiratory Volume in the first second; PA- Pseudomonas aeruginosa;   †indicates 
modified variables. *Original variable in the BSI includes frequency in the previous 1 
year.  
**Original Dyspnea variable included in the BSI is categorized according to Medical 
Research Council (MRC) scale: 1-3 (0 points), 4 (2 points), 5 (3 points): 
MRC: 1 – Not troubled by breathlessness except on strenuous exercise 
2 - Short of breath when hurrying on the level or walking up a slight hill 
3 – Walks slower than most people on the level, stops after a mile or so, or stops after 15 
minutes walking at own pace 
4 – Stops for breath after walking about 100 yards or after a few minutes on level ground 







Table 4.3  m-FACED severity markers distribution in the overall study sample and 












































































≤ 2 lobes affected 
















No reported Dyspnea 
(shortness of breath) 
Dyspnea (shortness 
of breath) when 
























m-FACED- modified FACED; PA- Pseudomonas aeruginosa; FEV1- Forced Expiratory 
Volume in the first second; † indicates modified variables. * Original Dyspnea variable 
included in FACED is dichotomized according to modified Medical Research Council 
(mMRC) scale: 0-2 (0 points); 3-4 on mMRC scale (1 point): 
0-Dyspnea only with strenuous exercise 
1 - Dyspnea when hurrying or walking up a slight hill 
2 – Walks slower than people of the same age because of dyspnea or has to stop for 
breath walking at own pace 
3 – Stops for breath after walking 100 yards or after a few minutes 






Table 4.4  Severity of bronchiectasis by m-BSI and m-FACED in the overall study sample and stratified by presence of PA* at 
baseline including and excluding PA from the severity scores calculation, n=1831    




















 (PA included in severity scores calculation)  (PA excluded from severity scores 
calculation) 












































m-BSI –modified Bronchiectasis Severity Index; m-FACED- modified FACED; PA- Pseudomonas aeruginosa; *- ≥1cultures positive 
for PA at baseline; 
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Low (n=426) 395 31 0 
Intermediate (n=755) 414 332 9 
High (n=650) 153 321 176 
Note: all data are shown as n; Kappa= 0.2632; m-BSI –modified Bronchiectasis Severity 





Table 4.6  Results of the unadjusted and adjusted multinomial logistic regressions for outcomes m-BSI and m-FACED including and 
excluding PA from the severity scores calculation, n=1,831 
 ORunadj (95% CI) ORadj (95% CI)*  ORunadj (95% CI) ORadj (95% CI)* 
 (PA included in severity scores 
calculation) 




High severity vs Low 

















      
m-FACED 
PA presence 
Severe vs Mild 

















m-BSI –modified Bronchiectasis Severity Index; m-FACED- modified FACED; PA- Pseudomonas aeruginosa; OR- Odds Ratio; CI- 
Confidence Interval; FEV1- Forced Expiratory Volume in the first second; * Adjusted for age, gender, baseline FEV1% predicted, 
NTM status and history of exacerbations in the past 2 years;  
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Figure 4.1  Distribution of m-BSI and m-FACED categories in the overall cohort and 
stratified by PA presence, n=1,831 
 






CHAPTER 5. CONCLUSION 
5.1 Summary 
The purpose of this dissertation research was to enhance the body of literature 
with new findings on symptom burden, disease severity and health-related behaviors in 
three chronic pulmonary diseases. This research utilized data from three different disease-
specific registries to conduct the analyses: 1) patients with Alpha1-Antitrypsin deficiency 
(AATD) enrolled in AlphaNet’s Disease Management And Prevention Program 
(ADMAPP); 2) COPD Foundation’s Patient-Powered Research Network (COPD PPRN) 
data on patients with a self-reported physician-diagnosed Chronic Pulmonary Obstructive 
Disease (COPD); and 3) the Bronchiectasis and NTM Research Registry (BRR) data 
collected from multiple US clinical sites on patients with Non-Cystic Fibrosis 
Bronchiectasis (NCFB) and Nontuberculous mycobacteria (NTM). 
Chapter Two of this research compared health and behavioral characteristics in 
patients with ZZ and SZ genotypes of AATD within ADMAPP to recognize the differing 
needs in health education and behavioral intervention between the two AATD 
genotypes.27 The findings demonstrated that individuals with SZ genotype had more 
frequent exacerbations as well as greater number of hospitalizations and physician visits 
compared to patients with more deficient ZZ genotype. These findings may be related to 
higher prior exposure of SZs to smoking and lower adherence to the recommendations of 
ADMAPP. SZs reported longer and heavier prior smoking history, and a greater 
proportion of them were current smokers. In addition, SZs had worse perception of their 
health, fitness and other health-related behaviors. Possible explanations may include that 
the perception of a lower disease risk in SZs may be associated with poor adherence to 
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healthy lifestyle recommendations of ADMAPP and considerably worse health status 
compared to more severely deficient ZZs.27 Of note, SZs in this study sample had 
significantly more comorbid conditions including hypertension, cerebrovascular disease, 
and were on average two years older than individuals with ZZ genotype. Also, SZs 
reported being less comfortable with their knowledge about the disease compared to ZZs. 
The lower adherence to ADMAPP and lack of knowledge about their condition, as well 
as poor health-related behavior choices, could be related to the self-perceived low 
seriousness of the disease in individuals with SZ genotype. Our study suggests that more 
severely AAT deficient ZZs are more adherent to disease management recommendations 
and maintain healthier lifestyles even though their condition is considered more severe. 
Chapter Three of this research estimated the patient-reported prevalence of 
moderate to severe cough and phlegm in people with COPD responding to the COPD 
PPRN survey. This study explored the association between severity of cough and phlegm 
and patient-reported outcomes including health-related quality of life. 
The burden of cough and phlegm among the study population was high with 
approximately 70% of the respondents reported moderate to high levels of cough and/or 
phlegm. Considering that cough and sputum production may be underreported in the 
COPD population81, symptom burden estimates based on patient-reported data have key 
importance. Significantly greater proportion of patients with moderate/high cough and 
phlegm reported being current smokers, had worse self-reported dyspnea and greater 




Our study findings demonstrated significant association between severity of 
cough and phlegm and greater levels of fatigue, anxiety, and depression, higher pain 
interference and sleep disturbance, and lower social abilities and physical function (as 
measured by the Patient Reported Outcome Measurement Information System (PROMIS) 
instrument). Other important findings from this chapter concern the longitudinal portion 
of this study. The patient-reported improvements in cough and phlegm over time were 
associated with better quality of life measured by PROMIS-29 at the follow-up. The 
findings of consistent association between high levels of cough and phlegm and worse 
patient-reported quality of life emphasize the need for new therapies specifically 
targeting these symptoms. 
Chapter Four of this research examined prevalence of Pseudomonas aeruginosa 
(PA) colonization and presence in sputum of NCFB patients within the BRR. This study 
posited the association between presence of PA and NCFB severity using two modified 
bronchiectasis severity assessment instruments. Over a quarter of the study population 
had presence of PA, and 13.6% presented with chronic PA colonization. Patients with PA 
presence had significantly worse pulmonary function as shown by FEV1 and FVC % 
predicted, and greater number of exacerbations and hospitalizations due to pulmonary 
illness, compared to those without PA. An important contribution of this work was to 
show that while the severity indices require chronic colonization of PA, evidence of a 
single PA infection was significantly associated with severity on both indices. 
The Bronchiectasis Severity Index (BSI), which was designed to identify patients 
at high risk for mortality, exacerbations, hospitalizations, and worse quality of life,25 and 
the FACED,26 were modified to adapt to the BRR data collection. Our findings supported 
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earlier reported differences in severity classification between the BSI and FACED.118 Our 
study demonstrated that m-BSI and m-FACED show fair agreement (kappa=0.2632) in 
classifying severity of NCFB. The results of the unadjusted and adjusted multinomial 
regression analyses demonstrated positive association between presence of PA and 
severity of bronchiectasis estimated using m-BSI and m-FACED. These findings support 
previous research and underline the importance of early identification and targeted 
treatment of PA to reduce disease severity. 
5.2 Strengths and Limitations 
This dissertation research assessing patient outcomes in people with three chronic 
pulmonary diseases yielded several important findings. One of the main strengths of this 
research is the large number of patients included in each study as well as detailed data 
collected on various demographic and clinical characteristics of the participants. In 
addition to the baseline, the COPD PPRN study also utilized follow-up data on patient-
reported outcomes after one year. Despite the richness of the data, the findings of this 
research should be interpreted with caution in view of several limitations related to the 
registry-based observational nature of the studies. 
Disease-specific registries and analyses based on patient registry data are gaining 
popularity.120 Systematic collection of data on specific diseases allows for follow-up of 
trends in diagnosis, treatment, and outcomes.121 The primary purpose of patient registries 
is mainly to aid in research of natural history of various diseases.121 In addition, registry 
data are also used for hypothesis generation, describing patient-reported outcomes, risk 
factors and exposures.121,122 
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Some of the limitations that are recognized in registry-based studies are selection 
bias, confounding by disease severity, channeling bias, immortal time bias, as well as 
several other limitations of the observational studies.120 In addition, research using only 
baseline data is not able to provide causal inference due to cross-sectional nature of the 
studies. 
This dissertation research is based on secondary data from several US disease-
specific registries. Chapter Two study utilized data collected from participants of 
AlphaNet, a not-for-profit health management organization that coordinates management 
and treatment of individuals with AATD and lung disease in the US27,42. Only patients 
with more severe genotypes ZZ and SZ were included in this study. Considering that a 
greater number ZZs develop lung disease relative to SZs, and only patients with lung 
disease were invited to enroll in ADMAPP, the potential of ascertainment bias cannot be 
excluded. In addition, the findings of this study cannot be generalized to patients with ZZ 
and SZ genotypes without lung disease. 
Chapter Three study is based on the COPD PPRN patient-reported data. Only data 
obtained from patients with self-reported physician-diagnosed COPD were included in 
this study, which may have introduced potential selection bias. In addition, self-reported 
data including presence of comorbidities, frequency of physician, ER visits and 
hospitalizations is subject to a recall bias. Another important to note limitation of this 
study is use of classification of severity of cough and phlegm based on CAT scores for 
questions pertaining to these symptoms, which is not a widely used classification and 
may have introduced a misclassification bias. 
88 
 
Chapter Four of this research utilized data collected from patients with NCFB 
within the BRR. The BRR is a multi-site registry, and participants are recruited from 
tertiary referral institutions and may not be representative of the general population of 
individuals with NCFB. In addition, patients within individual centers might be more 
correlated in their characteristics and therapy options. Our study analysis did not take into 
account potential variability in these characteristics across the clinical sites. These tertiary 
referral institutions have high interest in NTMLD; hence, the BRR population may be 
enriched for patients with NTM. The BRR data collection takes place using medical chart 
abstraction, which may have led to recording errors, missing entries and reporting and 
non-response biases. Another important limitation of this study is use of modified disease 
severity indices to adapt to the BRR data collection. 
Although disease-specific registries intrinsically are subject to potential biases 
and limitations, they often have the ability to address research questions that could 
potentially have a long-term influence on disease prevention and development of new 
therapies.10 In the case of uncommon and rare diseases such as AATD and 
bronchiectasis, registry-based studies often represent the only source of data for research. 
5.3 Future Research 
This dissertation research underlined many important recommendations for future 
research and considerations for management of chronic pulmonary diseases. Some 
prevalent chronic lung diseases, like COPD, are well researched, but further studies are 
needed to fully assess burden of specific symptoms of the disease such as cough and 
phlegm. The findings in Chapter Three highlight the needs for future research and 
development of new pharmacotherapies specifically targeting prevalent COPD symptoms 
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like cough and phlegm. Regrettably, no new and effective cough medication has been 
developed by the pharmaceutical industry in over a century.64 Future research is 
recommended to better understand patient-perceived burden of COPD symptoms, disease 
outcomes and quality of life including mood and social and physical functioning. Patient-
reported data is invaluable in assessing patient-perceived severity of disease, including its 
burden on daily life and activities. 
Less common respiratory diseases such as AATD and Bronchiectasis have started 
receiving a significant amount of attention from the scientific community leading to 
increased interest in research and development of new treatments. Disease-specific 
registries play important roles in continued research of these conditions, as frequently 
data collected by the registries is the largest source of information on natural history of 
rare diseases. 
The findings of the study in Chapter Two highlight the value of disease 
management programs in addressing many questions regarding the natural history of rare 
diseases such as AATD as well as sustained and tailored support provided to the patients 
with uncommon diseases. Our study findings underline the differences in demographic 
and clinical characteristics of patients with AATD with ZZ and SZ genotypes. Our results 
suggest that patients with less severe deficient genotype perceive their disease risk as low 
and do not fully comply with healthy lifestyle recommendations of the disease 
management program. Considering the above findings, future research should consider 
the extent to which genotype-specific health promotion intervention would be useful. 
Future studies should consider including collection of additional clinical data to enhance 
future outcome research. 
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As mentioned in Chapter Four, further research is needed to fully understand the 
multidimensional nature of NCFB. Pathogenic microorganisms such as Pseudomonas 
aeruginosa (PA) may potentially play a role in the development of bronchiectasis 
according to the “vicious cycle” hypothesis.24,79 Hence, early identification of prevalent 
pathogens such as PA and timely start of appropriate antibacterial therapy remain highly 
important in patients with NCFB.111 Future longitudinal studies are recommended to 
assess clinical outcomes and prognosis over time in this patient population. 
This dissertation research has contributed to the characterization of the 
epidemiology of chronic pulmonary disease burden. These studies expand the amount of 
knowledge available on disease severity, health behaviors and patient-perceived 
outcomes in three chronic lung diseases, and emphasize the need for further research and 
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